FIELD OF THE INVENTION:
The present invention relates to novel indanyl urea derivatives, their pharmaceutically
acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers,
polymorphs, hydrates and solvates. The present invention also encompasses process for
preparing novel compounds and pharmaceutical composition of said compounds. The
invention further relates to the use of the above mentioned compounds for the preparation of
medicament for use as pharmaceuticals.
BACKGROUND OF THE INVENTION:
The prevalence of airway diseases has increased in recent decades despite therapeutic
advances. Among the airway diseases, asthma exacerbations and chronic obstructive
pulmonary disease (COPD) are major causes of hospitalization. Both asthma and COPD
involve chronic inflammation of the respiratory tract. Despite the presentation of similar
symptoms, such as dyspnea, coughing, wheezing and expectoration, these airway diseases
have different underlying pathophysiological processes. COPD is a term which refers to a
large group of lung diseases characterized by obstruction of air flow that interferes with
normal breathing. Emphysema and chronic bronchitis are the most important conditions that
compose COPD. (Australian lung foundation, 2006). COPD involves chronic inflammation
of the peripheral airways and lung parenchyma, which leads to progressive narrowing of the
airways and shortness of breath. On the other hand Asthma is characterized by episodic
airway obstruction symptoms and usually starts early in life. The inflammation differs
markedly between asthma and COPD, with different cells, mediators, consequences and there
is a difference in response to corticosteroids (Clinics (Sao Paulo). 2012; 67(11):1335-43).
However, more recently it has become clear that severe asthma is much more similar to
COPD, with similarities in the inflammation and sharing a poor response to corticosteroids (
Allergy Clin Immunol. 2013;131(3):636-45). Interestingly, studies of molecular genetics are
now showing that severe asthma and COPD share several gene polymorphisms (Comp Funct
Genomics. 2012; 2012: 968267).
Chronic obstructive pulmonary disease (COPD) is a major global health problem that
is becoming prevalent, particularly in developing countries. It is one of the most common
diseases in the world, with a lifetime risk estimated to be as high as 25%, and now equally
affects both men and women (Nature Reviews 2013; 12: 543-559)
Current forms of therapy for COPD are relatively ineffective, as there are no drugs
available that considerably reduce disease progression or mortality or have a substantial
effect on exacerbations, which are one of the most common causes of hospital admissions.
Long acting bronchodilators are the mainstay of current COPD therapy. There have
been several advances in the development of 2-adrenergic receptor agonists and muscarinic
receptor antagonists that only need to be administered once a day. Moreover, long acting
2 adrenergic receptor agonists (LABAs) and long -acting muscarinic acetylcholine receptor
antagonists (LAMAs) have additive effects on bronchodilation and in the improvement of
symptoms, which has led to the development of LABA-LAMA combination inhalers.
However, although these drugs produce effective bronchodilation, they fail to treat the
underlying inflammatory disease in patients with COPD.
Alternatively or additional to bronchodilators, oral or inhaled corticosteroids could
also be used as COPD therapy. But corticosteroids have limitations as long term oral
corticosteroid therapy is not recommended and inhaled corticosteroids are known to be
associated with increased risk of pneumonia in patients (www.bcguidelines.ca) Moreover,
inhaled corticosteroids are found largely ineffective in significant number of COPD patients
as an anti- inflammatory therapy in COPD (Ann Fam Med. 2006; 4(3):253-62). Recently,
PDE-4 inhibitors have also been approved for treatment of severe COPD in adults; however,
such PDE-4 inhibitors have shown dose limiting side effects.(International Journal of COPD
2007; 2(2) : 121-129)
With better understanding of the pathophysiology of COPD disease process and
recognition of inflammation as an important feature, it is anticipated that disease modifying
therapy for COPD targeting underlying inflammation will prove effective the way it has been
successful in the treatment of other chronic inflammatory conditions like RA.
Many kinases are involved in the regulation of proinflammatory transcription factors
and inflammatory genes. The mitogen-activated protein kinase (MAPK) family includes the
p38 kinases, which consists of highly conserved proline-directed serine-threonine protein
kinases that are activated in response to inflammatory signals. The p38 MAPK pathway,
which is activated by cellular stress, regulates the expression of many inflammatory genes
that are involved in COPD (Nature Reviews 2013; 12: 543-559). Proinflammatory
cytokines/chemokines and environmental stress activates p38 mitogen activated protein
kinase (MAPK) by phosphorylation, which in turn activates p38 MAPK signaling pathway.
p38 is involved in the inflammatory responses induced by different stimuli through activation
and release of proinflammatory cytokines/chemokines, posttranslational regulation of these
genes, and activation of inflammatory cell migration. Therefore, p38 inhibitors present a
potentially attractive treatment target for the chronic inflammatory conditions including
COPD. Of the four isoforms known so far, p38 alpha is the most abundant in inflammatory
cells and has been the most studied.
Over the past two decades, p38 MAPK has been the subject of intense
multidisciplinary research. p38 MAPK inhibitors have been shown to be efficacious in
several disease models, including rheumatoid arthritis, psoriasis, Crohn's disease, and stroke.
Recent studies support a role for p38 MAPK in the development, maintenance, and/or
exacerbation of a number of pulmonary diseases, such as asthma, cystic fibrosis, idiopathic
pulmonary fibrosis, and chronic obstructive pulmonary disease. There is now an abundant
literature which demonstrates that p38 MAPK is activated in chronic inflammatory
conditions and that its activation results in the elaboration and release of further pro
inflammatory cytokines (Expert Opin. Investig. Drugs 2008; 17(10):1411-1425).
Though orally administered small molecule inhibitors targeted to p38 MAPK have
proved to be effective in reducing various parameters of inflammation in cells and tissues
obtained from patients with COPD in initial clinical studies, the major obstacle hindering the
definition and exploitation of the potential utilities of p38 MAPK inhibitors in the treatment
of human chronic inflammatory diseases has been the toxicity observed in patients. This has
been sufficiently severe to result in the withdrawal from clinical development of many of the
compounds progressed. Presently, none of them is yet approved anywhere in the world
because of one or the other problems associated with selected molecules such as toxicity or
selectivity (Expert Opin. Investig. Drugs 2008; 1 (10): 141 1-1425 & Chest
2011;139(6):1470-1479).
To overcome these problems of toxicity and selectivity of the target associated with
known p38 MAPK inhibitors, some alternative strategies were designed. One of them was to
design the treatment approaches wherein p38 kinase inhibitor is dosed directly to the
inflamed organ.
Other strategies include developing newer generation p38 MAPK inhibitors with
improved selectivity and lesser side effect profile.
There remains a need to identify and develop new p38 MAPK inhibitors which
provides desired therapeutic potential along with improved pharmacokinetic profile and/or
lesser side effects.
WO1998057937 discloses benzene derivatives as inhibitor of factor Xa with a neutral
PI specificity group.
WO200043384 discloses aromatic heterocyclic compounds for treating conditions
involving inflammatory diseases. Disclosed compounds said to inhibit the release of
inflammatory cytokines such as IL- 1 and TNF.
WO2003072569 discloses 1,4-disubstituted benzofused cycloalkyl urea compounds
in treating cytokine mediated disease.
US20080300281 discloses aryl and heteroaryl substituted heterocyclic ureas as p38
kinase inhibitor for the treatment of inflammatory or immunomodulatory diseases. Similarly,
WO2008125014 also discloses urea derivatives as p38 kinase inhibitor.
Present invention provides novel indanyl urea derivatives as p38 MAPK inhibitors,
which have demonstrated desired efficacy and safety profile.
SUMMARY OF THE INVENTION:
In one embodiment, the present invention provides novel compounds of formula (I),
(I)
their pharmaceutically acceptable salts and their isomers, stereoisomers, atropisomers,
conformers, tautomers, polymorphs, hydrates, and solvates;
wherein,
Y is C=O or C(Z');
Q is C or N, when Y is C=0 then Q is N;
When Y is C=0, Z is selected from hydrogen, -(Ci-C )alkyl, branched-(C3-C )alkyl, -(C3-
C6)cycloalkyl, -(Ci-C3)alkyl(C3-C6)cycloalkyl, -(Ci-C6)alkyl-OH, -(Ci-C6)alkyl-SH, -
C(0)CH 2R4, -(Ci-C6)alkyl-NR5R6, -(Ci-C6)alkyl-aryl, -(Ci-C6)alkyl-heteroaryl, -( -
C6)alkyl-C0 2H, -(Ci-C6)alkyl-C0 2R , -(Ci-C6)alkyl-C(0)NR 5R6, -C(0)NR 5R6, -C0 2R , -
COR , -(Ci-C6)alkyl-OR , -(Ci-C6)alkyl-S(0) R , -S(0) m-R , -S(0) mN(R3)-R ,
-S(0) mNR5R , aryl and heteroaryl, wherein said aryl or heteroaryl may be further optionally
substituted by 1-3 substituents independently selected from R ;
or when Y is C(Z'), Z and Z' together forms a 5 or 6 membered aromatic ring system having
1 to 3 heteroatoms independently selected from O, S(0) or N and the said ring is optionally
substituted by 1-3 substituents independently selected from
P is a cyclic ring, which is selected from
Where * denotes point of attachment to nitrogen;
Ra, Rb, and Rc are independently selected from hydrogen, halogen, -(Ci-C )alkyl, branched-
(C3-C )alkyl, -(C 3-C )cycloalkyl, aryl, heteroaryl, heterocyclic, -(Ci-C )alkyl-aryl, -( -
C6)alkyl-heteroaryl, hydroxyl, -CF3, -OCF3, -N0 2, -C(0)-(Ci-C 6)alkyl, -C(0)-(C 3-
C6)cycloalkyl, -C(0)CH 2R4, -NR5R6, -N(R3)C(0)-R , -N(R3)S(0) m-R , -N(R3)C(0)-N(R 3)-
R , -N(R3)C(S)N(R3)-R ,-OR , -C0 2H, -C0 2R , -C(0)-NR 5R6, -SH, -S(0) -R , -S(0) mN(R3)-
R , -S(0) m-NR5R6, -CN, -CHO, -(Ci-C6)alkyl-R4 and -(Ci-C6)alkyl-NR5R6, wherein each
aryl, heterocyclic or heteroaryl may be further optionally substituted with 1-3 substituents
independently selected from halogen, -(Ci-C )alkyl, branched-(C 3-C )alkyl, aryl, heteroaryl,
heterocyclic, hydroxyl, -CF3, -OCF3, -OR , -0-(Ci-C 6)alkyl-R , -N0 2, -C(0)-(Ci-C 6)alkyl, -
C(0)CH 2 R4, -NR5R6, -C0 2H, -C0 2R , -C(0)NR 5R6, -N(R3)C(0)-R , -N(R3)S(0) m-R , -
SH, -S(0) -R , -S(0) mN(R3)-R , -CN, -CHO, -(Ci-C6)alkyl-OR , -(Ci-C6)alkyl-halogen and -
(Ci-C6)alkyl-NR5R ; or any two substituents of Ra, Rb, and Rc may form a saturated, partially
saturated or unsaturated monocyclic ring, which may contain 0, 1, 2 or 3 ring heteroatoms
selected from O, S(0) or N;
W is -(CH2)t, -(CH2)mCO or -(CH2)mS(0) m;
R is selected from hydrogen, -(Ci-C )alkyl, branched-(C 3-C )alkyl, halogen, -0(Ci-C )alkyl,
-CF3, -OCF3 and hydroxyl;
R and R are independently selected from hydrogen, hydroxyl, -(Ci-C3)alkyl, branched-(C3-
C )alkyl and -(C3-C )cycloalkyl or Ri and R2 together with the carbon to which they are
attached, forms a -(C3-C )cycloalkyl ring in a spiro manner;
R3 is independently selected from hydrogen, -(Ci-C3)alkyl, branched-(C3-C )alkyl and -(Ci-
C3) alkyl(C3-C ) cycloalkyl, glucuronate;
R4 is independently selected from hydroxyl, -SH, -OR , -NR5R6, -S(0) -R , -S(0) -(Ci-
C6)alkyl-C0 2(Ci-C6)alkyl, -S(0) -(Ci-C6)alkyl-OH, -S(0) -(Ci-C6)alkyl-C0 2H, -N(R3)C(0)-
R , -N(R3)S(0) m-R , -0-(Ci-C 6)alkyl-C0 2(Ci-C6)alkyl, -0-(Ci-C 6)alkyl-OH and -0-(Ci-
C6)alkyl-C0 2H;
R5 and R are independently selected from hydrogen, -(Ci-C )alkyl, branched-(C3-C )alkyl, -
COR , -C(0)NR 5R6, -S(0) mR , -(Ci-C6)alkyl-(C3-C6)cycloalkyl, -(C3-C6)cycloalkyl, aryl and
heteroaryl or R and R are taken together with nitrogen to form a 3 to 8 membered
monocyclic or 8 to 12 membered bicyclic heterocycle ring, wherein the said mono and
bicyclic ring contain 0, 1, 2 or 3 ring heteroatoms selected from O, S(0) or N and the said
ring is optionally substituted by 1-3 substituents independently selected from R ;
R is independently selected from -(Ci-C )alkyl, -(Ci-C )alkyl-OH, branched-(C3-C )alkyl, -
(C3-C )cycloalkyl, -(Ci-C6)alkyl-(C3-C6)cycloalkyl, aryl and heteroaryl;
is independently selected from hydrogen, halogen, hydroxyl, -CN, -CHO, -N0 2, -(Ci-
C )alkyl, -(C3-C )cycloalkyl, -(Ci-C6)alkyl-(C3-C6)cycloalkyl, aryl, heteroaryl, heterocyclic,
-C(0)CH 2R4, -OR , -SH, -S(0) -R , -CF3, -OCF3, -C0 2H -COR , -C0 2R , -C(0)NR 5R6, -
S(0) mN(R3)-R and -NR5R6, wherein the said (Ci-C )alkyl, aryl, heterocyclic and heteroaryl
may be further substituted with 1-3 substituents independently selected from R9.
R 9 is independently selected from R , halogen, hydroxyl, -(Ci-C )alkyl-OH, -N0 2 -SH, -OR7
-0(Ci-C 6)alkyl-R4, -OC(0)-R , -0(Ci-C 6)alkyl-C0 2R , -0(Ci-C 6)alkyl-C0 2H -0(Ci-
C6)alkyl-C(0)-NR 5R6, -OS(0) m-R , -C0 2R , -C0 2H -C(0)-R , -C(0)-NR 5R6, -S(0) -R , -
S(0) (C1-C )alkyl-R4, -S(0) (C1-C )alkyl-C(0)NR 5R6, -S(0) (C1-C )alkyl-C0 2R , -S(0) (d-
C )alkyl-C0 2H, -NR5R , -S(0) m-NR5R6, -N(R3)C(0)-R , -N(R3)C(0)N(R 3)-R , -
N(R3)C(S)N(R3)-R , -N(R3)C(0)(Ci-C 6)alkyl-aryl,-N(R3)S(0) m-R OS0 3H and Oglucuronate;
m is 1 or 2;
n is 0, 1 or 2;
t is 2 or 3.
In another embodiment, the present invention pertains to a compound as above,
however only including pharmaceutically acceptable salts thereof.
In another embodiment, the present invention provides a method for preparation of a
compound of formula (I) as herein described in Schemes 1 to 3.
In another embodiment, the present invention includes synthetic intermediates that are
useful in preparing the compounds of formula (I) and process for preparing such
intermediates.
In another embodiment, the present invention is a pharmaceutical composition
comprising a compound of formula (I), optionally in admixture with a pharmaceutically
acceptable adjuvant or carrier.
Another embodiment of the present invention is a method for treating allergic and
non-allergic airway diseases by administering a therapeutically effective amount of a
compound of formula (I) to a mammal, including human being, in need thereof.
Another embodiment of the present invention is a method for treating chronic
obstructive pulmonary disease and asthma by administering a therapeutically effective
amount of a compound of formula (I) to a mammal, including human being, in need thereof.
Another embodiment of the present invention is the use of a compound of formula (I)
for the preparation of a medicament for treating allergic and non-allergic airway diseases.
Another embodiment of the present invention is the use of a compound of formula (I) for the
preparation of a medicament for treating chronic obstructive pulmonary disease and asthma.
FIGURES
Fig 1: Effect of treatment of compound no 43 on lung function parameters; 1.
Functional residual capacity (Fig la), 2. Residual volume of lungs (Fig lb).
Fig 2: Effect of treatment of compound no 43 on lung function parameters; 1.
Inspiratory capacity (IC) to total lung capacity ratio (TLC) (Fig 2a) and 2. Residual volume
(RV) to total lung capacity (TLC) ratio (Fig 2b).
DETAILED DESCRIPTION OF THE INVENTION:
In one embodiment, the present invention provides novel compounds of formula (I),
(I)
their pharmaceutically acceptable salts and their isomers, stereoisomers, atropisomers,
conformers, tautomers, polymorphs, hydrates and solvates, wherein R, R1 R2, R3, P, W, Q,
Y and Z, are as defined above.
In a preferred embodiment, the present invention provides novel compounds of
formula (I),
(I)
their pharmaceutically acceptable salts and their isomers, stereoisomers, atropisomers,
conformers, tautomers, polymorphs, hydrates and solvates;
wherein,
Y is C=O or C(Z');
Q is C or N; when Y is C=0 then Q is N;
When Y is C=0, Z is selected from hydrogen, -(Ci-C )alkyl, branched-(C3-C )alkyl, -(C3-
C6)cycloalkyl, -(Ci-C3)alkyl(C3-C6)cycloalkyl, -(Ci-C6)alkyl-OH, -(Ci-C6)alkyl-aryl, -(QC
6)alkyl-C(0)NR 5R6, S(0) m-R and aryl;
or when Y is C(Z'), Z and Z' together forms a 5 or 6 membered aromatic ring system having
1 to 3 heteroatoms independently selected from S(0) or N and the said ring is optionally
substituted by 1-2 substituents independently selected from
P is a c clic ring, which is selected from
Where * denotes point of attachment of nitrogen;
Ra, Rb, and Rc are independently selected from hydrogen, halogen, -(Ci-C )alkyl, branched-
(C3-C6)alkyl, -(C3-C6)cycloalkyl, hydroxyl, -N(R3)S(0) m-R , -N(R3)COR and -OR ;
W is -(CH2)t or -(CH2)mCO;
R is hydrogen or -(Ci-C )alkyl;
Ri and R2 are independently selected from hydrogen and hydroxyl;
R3 is independently selected from hydrogen and glucuronate;
R4 is selected from hydroxyl and -NR5R ;
R5 and R is independently selected from hydrogen, -(Ci-C )alkyl and -COR or
R and R are taken together with nitrogen to form a 3 to 8 membered monocyclic
heterocycle ring, wherein the said monocyclic ring contain 0, 1, 2 or 3 ring heteroatoms
selected from O or N;
R is selected from -(Ci-C )alkyl, -(C3 -C )cycloalkyl, -(Ci-C )alkyl-OH and branched-(C3-
C6)alkyl;
is independently selected from hydrogen, -(C3 -C )cycloalkyl, aryl, heteroaryl, -CF 3
-CO 2R7 and -NR5R , wherein the said aryl or heteroaryl may be further substituted with 1-3
substituents selected from R9.
R 9 is independently selected from halogen, R , hydroxyl, -OR -0(Ci-C )alkyl-R4, -S(0) -R
-S(0) (Ci-C 6)alkyl-R4 , -(Ci-C 6)alkyl-OH and O-glucuronate;
m is 1 or 2;
n is 0;
t is 2 or 3.
In a most preferred embodiment, the present invention provides novel compounds of
formula (I),
(I)
their pharmaceutically acceptable salts and their isomers, stereoisomers, atropisomers,
conformers, tautomers, polymorphs, hydrates and solvates;
wherein Q=N and R, R1 R2, R3, P,W, Y and Z, are as defined above,
A family of specific compounds of particular interest within the above formula (I)
consists of compound and pharmaceutically acceptable salts thereof as follows:
Compd. Chemical Name
No.
1 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
Compd. Chemical Name
2,3-dihydro-lH-inden-4-yl)urea
2 l-[3-tert-butyl-l-(4-tert-butylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
3 l-[3-tert-butyl-l-(4-cyclohexylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
4 l-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-(7-{2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
5 l-(3-tert-butyl-l -phenyl- lH-pyrazol-5-yl)-3-(7- {2-[3-(2-methoxyphenyl)-
5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-oxoethoxy}-2,3-
dihydro- 1H-inden-4-yl)urea
6 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-(7- {2-[4-(2-
hydroxyethyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
7 1-(3-tert-butyl-1-phenyl- 1H-pyrazol-5-yl)-3-[7-(2- {3-[2-
(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}-
2-oxoethoxy)-2,3-dihydro-lH-inden-4-yl]urea
8 1-[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-(7-{2-[3-
(2-methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-
oxoethoxy}-2,3-dihydro-lH-inden-4-yl)urea
9 1-[3-tert-butyl-1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-[7-(2- {3-
[2-(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}-2-oxoethoxy)-2,3-dihydro-lH-inden-4-yl]urea
10 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-[7-(2- {3-[2-
(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}-
2-oxoethoxy)-2,3-dihydro-lH-inden-4-yl]urea
11 1-(3-tert-butyl-1-phenyl- 1H-pyrazol-5-yl)-3-(7- {2-[3-(2- {[2-(morpholin-4-
yl)ethyl]sulfanyl}phenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]-2-oxoethoxy}-2,3-dihydro-lH-inden-4-yl)urea
12 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]ethoxy}-2,3-dihydro- 1H-inden-4-
yl)urea
13 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-[7-(2- {3-[2-
(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
14 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(2-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
15 1-[3-tert-butyl-1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
Compd. Chemical Name
2,3-dihydro-lH-inden-4-yl)urea
16 1-{7-[2-(4-benzyl-3 -oxopiperazin- 1-yl)ethoxy] -2,3-dihydro- 1H-inden-4-yl }-
3-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl]urea
17 l-[3-tert-butyl-l-(4-methoxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
18 1-[3-tert-butyl- 1-(4-hydroxyphenyl)- 1H-pyrazol-5 -yl] -3-(7-{2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
19 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-{7-[2-(3-oxo-4-
phenylpiperazin- 1-yl)ethoxy]-2,3-dihydro- 1H-inden-4-yl }urea
20 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-{2-[2-
(morpholin-4-yl)ethoxy]phenyl}-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
2 1 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-(7- {2-[4-
(cyclopentylmethyl)-3-oxopiperazin-l-yl]ethoxy}-2, 3-dihydro- lH-inden-4-
yl)urea
22 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[4-
(cyclobutylmethyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-lH-inden-4-
yl)urea
23 1-[3-tert-butyl- 1-(4-ethylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(2-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
24 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-[7-(2- {3-
[2-(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
25 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-
(2-methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
26 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-
(2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
27 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-
(2-propoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
28 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{3-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]propoxy }-2,3-dihydro- 1H-inden-
4-yl)urea
29 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(3-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
Compd. Chemical Name
2,3-dihydro-lH-inden-4-yl)urea
30 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-[7-(2- {3-[2-(2-
hydroxyethoxy)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
3 1 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-chloro-4-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
32 l-(7-{2-[3-(2-butoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)-3-[3-tert-butyl-l-(4-
methylphenyl)-lH-pyrazol-5-yl]urea
33 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-[2-
(propylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
34 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(4-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
35 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-[7-(2- {3-
[2-(propylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
36 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
37 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(2,4-
dihydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
38 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-4-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
39 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-2,3-dihydro- 1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)methanesulfonamide
40 N-(5-tert-butyl-3-{ [(7-{2-[3-(2-hydroxyphenyl)-5,6-
dihydrof 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro- 1Hinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)methanesulfonamide
4 1 N-(5-tert-butyl-3- {[(7- {3-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]propoxy}-2,3-dihydro-lH-inden-4-yl)carbamoyl]amino}-2-
methoxyphenyl) methanesulfonamide
42 N-[5-tert-butyl-2-methoxy-3-({[7-(2-{3-[2-(propylsulfanyl)phenyl]-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}ethoxy)-2,3-dihydro-lHinden-
4-yl]carbamoyl}amino)phenyl]methanesulfonamide
Compd. Chemical Name
43 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
methoxyphenyl)ethanesulfonamide
44 N-{5-tert-butyl-3-[( {7-[2-(4-butyl-3-oxopiperazin- 1-yl)ethoxy] -2,3-dihydro-
1H-inden-4-yl }carbamoyl)amino]-2-methoxyphenyl } methanesulfonamide
45 N-[5-tert-butyl-2-methoxy-3-({[7-(2- {3-[2-(methylsulfanyl)phenyl]-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}ethoxy)-2,3-dihydro-lHinden-
4-yl]carbamoyl}amino)phenyl]ethanesulfonamide
46 N-(5-tert-butyl-3-{ [(7-{2-[3-(3-hydroxyphenyl)-5,6-
dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy }-2,3-dihydro- 1Hinden-
4-yl)carbamoyl] amino }-2-methoxyphenyl)methanesulfonamide
47 N-(5-tert-butyl-3-{[(7-{2-[3-{4-[(2-hydroxyethyl)sulfanyl]phenyl}-5,6-
dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy }-2,3-dihydro- 1Hinden-
4-yl)carbamoyl] amino }-2-methoxyphenyl)methanesulfonamide
48 N-(5-tert-butyl-3-{[(7-{2-[3-(5-chloro-2-hydroxyphenyl)-5,6-
dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy }-2,3-dihydro- 1Hinden-
4-yl)carbamoyl] amino }-2-methoxyphenyl)methanesulfonamide
49 N-(5-tert-butyl-3-{ [(7-{2-[3-(2,4-dihydroxyphenyl)-5,6-
dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy }-2,3-dihydro- 1Hinden-
4-yl)carbamoyl] amino }-2-methoxyphenyl)ethanesulfonamide
50 N-[5-tert-butyl-2-methoxy-3-({[7-(2-{3-[2-(propylsulfanyl)phenyl]-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}ethoxy)-2,3-dihydro-lHinden-
4-yl]carbamoyl }amino)phenyl] ethanesulfonamide
5 1 N-(5-tert-butyl-3-{[(7-{2-[3-(5-chloro-2-hydroxyphenyl)-5,6-
dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy }-2,3-dihydro- 1Hinden-
4-yl)carbamoyl] amino }-2-methoxyphenyl)ethanesulfonamide
52 N-[5-( {[7-( {[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}acetyl)-4, 5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl] acetamide
53 l-[3-tert-butyl-l-(3-chloro-4-methoxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-
oxo-2-[3-(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy} -2,3-dihydro- lH-inden-4-yl)urea
54 ethyl 6-({ [7-({ [3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}acetyl)-2-
[(cyclopropylcarbonyl)amino]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-
carboxylate
55 N-[5-( {[7-( {[3-tert-butyl- 1-(4-cyclohexylphenyl)- 1H-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}acetyl)-4, 5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl]acetamide
56 l-[3-tert-butyl-l-(3-chloro-4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-oxo-
2-[3-(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
Compd. Chemical Name
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
57 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-{7-[2-oxo-2-(3 -
phenyl-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethoxy]-2,3-
dihydro- 1H-inden-4-yl }urea
58 l-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-(7-{2-[3-(3-chloro-4-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-
oxoethoxy}-2,3-dihydro-lH-inden-4-yl)urea
59 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-{7-[2-(3-oxo-4-
propylpiperazin- 1-yl)ethoxy] -2,3-dihydro- 1H-inden-4-yl }urea
60 l-[3-tert-butyl-l-(4-fluorophenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
61 1-(3-tert-butyl- 1-phenyl- 1H-pyrazol-5-yl)-3-(7- {2-[4-(cyclopropylmethyl)-
3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
62 1-[3-tert-butyl- 1-(2-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
63 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-
(2,4-dihydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
64 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
methoxyphenyl)cyclopropanecarboxamide
65 1-[3-tert-butyl- 1-(3-chloro-4-hydroxyphenyl)- lH-pyrazol-5-yl] -3- {7-[2-(3-
cyclohexyl-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethoxy]-2,3-
dihydro- 1H-inden-4-yl }urea
66 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
6-methyl-2,3-dihydro-lH-inden-4-yl)urea
67 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(naphthalenl-
yl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-
dihydro- 1H-inden-4-yl)urea
68 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-{7-[2-(3-cyclohexyl-
5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethoxy]-2,3-dihydro-lHinden-
4-yl}urea
69 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-methyll-
benzofuran-2-yl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy} -2,3-dihydro- lH-inden-4-yl)urea
70 l-[3-tert-butyl-l-(3,4,5-trimethoxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
Compd. Chemical Name
yl)urea
7 1 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea methanesulfonate (1:1)
72 N-{5-tert-butyl-3-[({7-[2-(3-cyclohexyl-5,6-dihydro[l,2,4]triazolo[4,3-
a]pyrazin-7(8H)-yl)ethoxy]-2,3-dihydro-lH-inden-4-yl}carbamoyl)amino]-
2-methoxyphenyl }methanesulfonamide
73 N-(5-tert-butyl-3-{[(7-{2-[3-(5-chloro-2-hydroxyphenyl)-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-6-methyl-2,3-
dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
methoxyphenyl)methanesulfonamide
74 N-(5-tert-butyl-2-methoxy-3-{[(7-{2-[3-(naphthalen-l-yl)-5,6-
dihydro[ 1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy }-2,3-dihydro- 1Hinden-
4-yl)carbamoyl]amino}phenyl)methanesulfonamide
75 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[4-
(ethylsulfonyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-lH-inden-4-
yl)urea
76 2-[7-(2- {[7-( {[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}ethyl)-5,6,7,8-
tetrahydro[l,2,4]triazolo[4,3-a]pyrazin-3-yl]-4-chlorophenyl
hexopyranosiduronic acid
77 N-{[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl]carbamoyl }-N-(7- {2-
[3-(5-chloro-2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]ethoxy} -2,3-dihydro- lH-inden-4-yl)hexopyranuronosylamine
78 N-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-N-[(7-{2-[3-(5-chloro-
2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy} -2,3-dihydro- lH-inden-4-yl)carbamoyl]hexopyranuronosylamine
79 2-{4-[2-({7-[({5-tert-butyl-2-methoxy-3-
[(methylsulfonyl)amino]phenyl}carbamoyl)amino]-2,3-dihydro-lH-inden-4-
yl }oxy)ethyl] -2-oxopiperazin- 1-yl }-N,N-dimethylacetamide
80 2-[4-(2-{ [7-({ [3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}ethyl)-2-
oxopiperazin- 1-yl]-N,N-dimethylacetamide
8 1 N-{5-tert-butyl-3-[({7-[2-(4-cyclopropyl-3-oxopiperazin-l-yl)ethoxy]-2,3-
dihydro- 1H-inden-4-yl }carbamoyl)amino]-2-
methoxyphenyl }methanesulfonamide
82 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
hydroxyphenyl)ethanesulfonamide
Compd. Chemical Name
83 N-(5-tert-butyl-3- {[(7- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- l -
yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
methoxyphenyl)ethenesulfonamide
84 1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-[7-(2- {3-[2-
(hydroxymethyl)phenyl]-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl }ethoxy)-2,3-dihydro- lH-inden-4-yl]urea
85 l-[3-tert-butyl- l -(4-methylphenyl)- lH-pyrazol-5-yl]-3-(7- {3-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]propoxy}-2,3-dihydro- lH-inden-4-yl)urea
86 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(pyridin-2-
yl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy} -2,3-dihydro-
1H-inden-4-yl)urea
87 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(2-
ethylphenyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy} -2,3-
dihydro- 1H-inden-4-yl)urea
88 1-[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl] -3-(7- {2-[3-(4-chloro-2-
hydroxyphenyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro- lH-inden-4-yl)urea
89 l-[3-tert-butyl- l -(4-methylphenyl)- lH-pyrazol-5-yl]-3-(7- {2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro- lH-inden-4-yl)urea methanesulfonate
90 l-[3-tert-butyl- l -(4-methylphenyl)- lH-pyrazol-5-yl]-3-(7- {2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[ l ,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro- 1H-inden-4-yl)urea hydrochloride
DEFINITIONS:
The following definitions apply to the terms as used throughout this specification,
unless otherwise limited in specific instances:
The term "compound" employed herein refers to any compound encompassed by the
generic formula disclosed herein. The compounds described herein may contain one or more
double bonds and therefore, may exist as isomers, stereoisomers, such as geometric isomers,
E and Z isomers, and may possess asymmetric carbon atoms (optical centers) and therefore
may exist as enantiomers or diastereoisomers. Accordingly, the chemical structures described
herein encompasses all possible stereoisomers including the stereoisomerically pure form
(e.g., geometrically pure) and stereoisomeric mixtures (racemates). The compound described
herein, may exist as a conformational isomers such as chair or boat form. The compound
described herein may also exist as atropisomers. The compounds may also exist in several
tautomeric forms including the enol form, the keto form and mixtures thereof. Accordingly,
the chemical structures described herein encompass all possible tautomeric forms of the
compounds. The compounds described also include isotopically labeled compounds where
one or more atoms have an atomic mass different from the atomic mass conventionally found
in nature. Examples of isotopes that may be incorporated into the compounds of the invention
include, but are not limited to 2H, 3H, 13C, 14C, 15N, 18O, 17O, etc. Compounds may exist in
unsolvated forms as well as solvated forms, including hydrated forms. In general, compounds
may be hydrated or solvated. Certain compounds may exist in multiple crystalline or
amorphous forms. In general, all physical forms are equivalent for the uses contemplated
herein and are intended to be within the scope of the present invention.
The use of the terms "a" & "an" & "the" and similar referents in the context of
describing the invention (especially in the context of the following claims) are to be
construed to cover both the singular and the plural, unless otherwise indicated herein or
clearly contradicted by context.
The nomenclature of the compounds of the present invention as indicated herein is
according to ACD/Lab's Name Program (Version 12.0).
"Pharmaceutically acceptable salt" refers to a salt of a compound, which possesses
the desired pharmacological activity of the parent compound. Such salts include: (1) acid
addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid,
sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and the like; or formed with organic
acids such as acetic acid, propionic acid, isobutyric acid, hexanoic acid,
cyclopentanepropionic acid, oxalic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid,
succinic acid, suberic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid,
benzoic acid, 3-(4-hydroxybenzoyl) benzoic acid, phthalic acid, cinnamic acid, mandelic
acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-
hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-
naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-
methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic
acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid,
glucuronic acid, galactunoric acid, glutamic acid, hydroxynaphthoic acid, salicylic acid,
stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in
the parent compound is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth
ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine,
diethanolamine, triethanolamine, N-methylglucamine and the like. Also included are salts of
amino acids such as arginate and the like (see, for example, Berge, S.M., et al.,
"Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Alternatively,
compounds of present invention can also form co-crystal with the mentioned acids, base or
ions, which is included within the scope of pharmaceutically acceptable salt.
As used herein, the term "polymorph" pertains to compounds having the same
chemical formula, the same salt type and having the same form of hydrate/solvate but having
different crystallographic properties.
As used herein, the term "hydrate" pertains to a compound having a number of water
molecules bonded to the compound.
As used herein, the term "solvate" pertains to a compound having a number of solvent
molecules bonded to the compound.
The present invention also encompasses compounds which are in a prodrug form.
Prodrugs of the compounds described herein are those compounds that readily undergo
chemical changes under physiological conditions (in vivo) to provide the compounds of the
present invention. Additionally, prodrugs can be converted to the compounds of the present
invention by chemical or biochemical methods in an ex vivo environment, for example,
transdermal patch reservoir with a suitable enzyme or chemical. Prodrugs are, in some
situation, easier to administer than the parent drug. They may, for instance, be bioavailable
by oral administration whereas the parent drug is not. The prodrug may also have improved
solubility in pharmacological composition over the parent drug. Esters, peptidyl derivatives
and the like, of the compounds are the examples of prodrugs of the present invention. In vivo
hydrolysable (or cleavable) ester of a compound of the present invention that contains a
carboxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the
human or animal body to produce the parent acid.
The term "substituted", as used herein, includes mono- and poly-substitution by a
named substituent to the extent such single and multiple substitution (including multiple
substitution at the same site) is chemically allowed and which means that any one or more
hydrogens on the designated atom is replaced with a selection from the indicated group,
provided that the designated atom's normal valence is not exceeded, and that the
substitution results in a stable compound, for example, when a substituent is keto, then the
two hydrogens on the atom are replaced. All substituents (R, R1 R2 ....) and their further
substituents described herein may be attached to the main structure at any heteroatom or
carbon atom which results in formation of stable compound.
As used herein, a "halogen" substituent is a monovalent halogen radical chosen from
chloro, bromo, iodo and fluoro.
The term "(Ci-C 3)alkyl" or "(Ci-C 6)alkyl" used either alone or in attachment with
another group refers to a saturated aliphatic hydrocarbon radical having the 1 to 3 or 1 to 6
carbon atoms respectively and that is unsubstituted or substituted. Said "(Ci-C 3)alkyl" or
"(Ci-C 6)alkyl" is straight chain for example, methyl, ethyl, n-propyl, n-butyl, n-pentyl, nhexyl
and it may contain one or two double or triple bonds. The said "(Ci-C 3)alkyl" or (Ci-
C )alkyl may also contain (C3-C )cycloalkyl ring in a spiro manner.
The term "branched(C3-C )alkyl" as used herein refers to a saturated aliphatic
hydrocarbon radical having the 3 to 6 carbon atoms that is unsubstituted or substituted. Said
alkyl includes branched chain for example isopropyl, isobutyl, sec-butyl, tert-butyl and it
may suitably contain one or two double or triple bonds.
The term "(C 3-C6) cycloalkyl" used either alone or in attachment with another group
refers to a cyclic ring system having the 3 to 6 carbon atoms and that may be unsubstituted or
substituted. The said "(C 3-C )cycloalkyr' means a cyclic ring system containing only carbon
atom in the ring system backbone such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl.
Cycloalkyl may have any degree of saturation provided that at least one ring in the ring
system is not aromatic.
The term "aryl" refers to an aromatic group for example, which is a 6 to 10 membered
monocyclic or bicyclic carbon-containing ring system. The aryl groups include, but are not
limited to, phenyl, naphthyl, biphenyl, tetrahydronaphthyl and indanyl. Preferably, aryl is
phenyl, indanyl or naphthyl.
The term "heteroaryl" refers to an aromatic group for example, which is a 5 to 14
membered monocyclic or bicyclic ring system, which has at least one heteroatom. The term
"heteroatom" as used herein includes O, N, S(0) wherein n is as defined above. In bicyclic
ring system, ring can be fused through a bridge heteroatom. The heteroaryl groups include,
but are not limited to pyrrolyl, furanyl (furyl), thiophenyl (thienyl), pyrazolyl, imidazolyl,
oxazolyl, isoxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl
(pyridyl), pyridazinyl, pyrimdinyl, pyrazinyl, triazinyl, indolyl, benzofuranyl,
benzothiophenyl (benzothienyl), indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl,
benzothiazolyl, quinolinyl, isoquinohnyl, cinnolinyl, quinazohnyl, quinoxahnyl, phthalazinyl
or naphthyridinyl. Preferably heteroaryl is pyridinyl, thiophenyl, furanyl, pyrazolyl,
imidazolyl, triazinyl or benzofuranyl.
The term "heterocyclic" or "heterocycle ring" refers to a fully or partially saturated
cyclic group, for example, which is a 3 to 14 membered monocyclic or bicyclic ring system,
which has at least one heteroatom. The term "heteroatom" as used herein includes O, N,
S(0) wherein n is as defined above. In bicyclic heterocyclic system, at least one ring is not
aromatic and the rings can also be attached to each other in a spiro manner. The heterocycle
groups include, but are not limited, oxiranyl, aziridinyl, oxetanyl, azetidinyl, pyrrolidinyl,
dihydropyrrolyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydro thiophenyl, dihydrothiophenyl,
pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazoiidinyl, thiazoiidinyl, triazolidinyl,
oxadiazolidinyl, piperidinyl, tetrahydropyridinyl, dihydropyridinyl, piperazinyl, piperzinone,
tetrahydropyranyl, dioxanyl, morpholinyl, thiomorpholinyl, triazinanyl, azepanyl, diazepanyl,
diazepinyl, oxepanyl, dioxepanyl, oxazepanyl, oxazepinyl, indolinyl, benzomorpholinyl,
tetrahydroquinolyl or tetrahydrisoquinolyl. Preferably heterocyclic is piperazinyl,
piperzinone, morpholinyl, thiomorpholinyl, pyrrolidinyl or piperidinyl.
As used herein, "hydroxyl" refers to -OH group.
As used herein, "room temperature" refers to a temperature between 20 C and 30 C.
As used herein, the term "mammal" means a human or an animal such as monkeys,
primates, dogs, cats, horses, cows, etc.
The terms "treating" or "treatment" of any disease or disorder as used herein to mean
administering a compound to a mammal in need thereof. The compound may be administered
thereby providing a prophylactic effect in terms of completely or partially preventing or
delaying the onset of a disease or disorder or sign or symptom thereof; and/or the compound
may be administered thereby providing a partial or complete cure for a disease or disorder
and/or adverse effect attributable to the disorder.
The phrase "a therapeutically effective amount" means the amount of a compound
that, when administered to a patient for treating a disease, is sufficient to effect such
treatment for the disease. The "therapeutically effective amount" will vary depending on the
compound, mode of administration, the disease and its severity and the age, weight, etc., of
the patient to be treated.
Throughout this specification and the appended claims it is to be understood that the
words "comprise" "has" and "include" and variations such as "comprises", "comprising",
"having", "includes", "including" are to be interpreted inclusively, unless the context requires
otherwise. That is, the use of these words may imply the inclusion of an element or elements
not specifically recited.
Also included within the scope of the invention are metabolites of compounds of
formula (I), that is, compounds formed in vivo upon administration of the drug. Some
examples of metabolites in accordance with the invention include following compounds-
Compd. Chemical Name
91 N-(5-tert-butyl-3- {[(4- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]ethoxy}-lH-inden-7-yl)carbamoyl]amino}-2-
methoxyphenyl)ethenesulfonamide
92 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-2-hydroxy-2,3-dihydro-lH-inden-4-yl)carbamoyl]amino}-2-
methoxyphenyl)ethanesulfonamide
93 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-3-hydroxy-2,3-dihydro-lH-inden-4-yl)carbamoyl]amino}-2-
Compd. Chemical Name
methoxyphenyl)ethanesulfonamide
94 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-2,3-dihydro- 1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)-2-hydroxyethanesulfonamid
95 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-1-hydroxy-2,3-dihydro- 1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)ethanesulfonamide
96 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)ethanesulfonamide
97 N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
ethoxy}-1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)ethenesulfonamide
98 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
3-hydroxy-2,3-dihydro-lH-inden-4-yl)urea
99 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
1-hydroxy-2,3-dihydro-lH-inden-4-yl)urea
100 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2-hydroxy-2,3-dihydro-lH-inden-4-yl)urea
101 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydroxy-2,3-dihydro-lH-inden-4-yl)urea
102 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(4-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
1-hydroxy- 1H-inden-7-yl)urea
103 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2-hydroxy- 1-(hydroxymethyl)-2,3-dihydro- lH-inden-4-yl]urea
104 l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
1-(hydroxymethyl)- lH-inden-4-yl]urea
105 1-{3-tert-butyl-1-[4-(hydroxymethyl)phenyl]-1H-pyrazol-5-yl }-3-(7-{2-[3-
(5-chloro-2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy} -2,3-dihydro- lH-inden-4-yl)urea
106 1-{3-tert-butyl- l-[4-(hydroxymethyl)phenyl]- 1H-pyrazol-5-yl} -3-(7- {2-[3-
(5-chloro-2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-1H-inden-4-yl)urea
Compd. Chemical Name
(5-chloro-2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-1H-inden-7-yl)urea
In another embodiment, present invention provides the process for preparing the
compounds of formula (I).
The following reaction schemes are given to disclose the synthesis of the compounds
according to the present invention.
Accordingly, the compounds of formula (I) of the present invention may be prepared
as described in the schemes below.
Illustrative embodiments of compounds of formula I include compounds of formula IA,
formula I-B, formula I-C and formula I-D. In which the substituents are as defined in
connection with general formula I and schemes 1-3.
Scheme 1:
Synthesis of compounds of formula I-A, where substituents of general formula (I)
such as R3 is hydrogen, Y is C=0 and Q is N, is shown in scheme 1. Other substitutions of
formula (I) such as R, R1 R2, Z, P and W are same as defined above. Compound of formula
I-A can be prepared by the reaction of appropriate carbamate of formula VII and amine of
formula VI in the presence of suitable amine such as ,-diisopropylethylamine (DIEA) in
aprotic solvent such as isopropyl acetate, ethyl acetate or THF at room to reflux temperature.
Compound of formula VI can be prepared by the Boc deprotection of compound of formula
V using strong acids such as trifluoroacetic acid (TFA) in suitable solvent such as methylene
dichloride (MDC) at 0°C to room temperature. Compound of formula V is prepared by the
reaction of hydroxyindane compound of formula IV with appropriate chloro compound of
formula III. This reaction is carried out in the presence of suitable base such as potassium
carbonate (K2CO3) and solvent such as acetonitrile (CH 3CN), THF, DMF or Dioxane at room
temperature to 80 °C. Compound of formula III is prepared by the N-alkylation of compound
of formula II with suitable halides. The reaction is carried out in the presence of suitable base
such as K2CO3 and solvent such as dimethyl formamide (DMF) at 0°C to room temperature.
Scheme 2:
Synthesis of various compounds of formula I-B and I-C is shown in scheme 2,
wherein substituents of general formula (I) are defined such as is phenyl, R3 is hydrogen,
Q is N, Y is C(Z') and Z and Z' forms a heteroaryl ring. Other substitutions of formula (I)
such as R, R1 R2, P, R and W are same as defined above. Compound of formula XI or XII
is reacted, separately, with appropriate carbamate VII to obtain the compound of formula I-B
and I-C, respectively, using similar condition as described for compounds of formula I-A as
shown in scheme 1. Compound of formula X, where one of Rg is OMe, is demethylated to
yield the compound of formula XI. This reaction is performed using boron tribromide (BBr3)
in suitable solvent such as MDC at 0°C to room temperature. In this case, Boc deprotection
also occurs in situ. Boc deprotection of formula X is carried out in trifluoroacteic acid in
solvent MDC to yield the compound of formula XII. Compounds of formula X is
synthesized from compounds of formula IX using similar condition as described for
compounds of formula V as shown in scheme 1. Similarly, compounds of formula IX is
obtained from compounds of formula VIII using similar procedure as described for
compounds of formula III as delineated in scheme 1. The OH group of formula I-B can be
further derivatized using conventional methods known to a person skilled in the art.
Scheme 3:
Compounds of formula I-D, wherein substituents of general formula (I) are defined
such as R3 is hydrogen, Q is C,W is -(CH2)mCO, Y is C(Z') and Z and Z' forms a heteroaryl
ring, are synthesized as shown in scheme 3. Other substitutions of formula (I) such as R, R1
R2, P, m and R are same as defined above. Compound of formula XVII is reacted with
appropriate carbamate VII to obtain the compound of formula I-D using similar condition as
described for compounds of formula I-A as shown in scheme 1. Boc deprotection of
compounds of formula XVI is carried out to yield the compounds of formula XVII using
similar condition as described for compounds of formula VI. Compounds of formula XVI is
synthesized from reaction of compounds of formula XV and compound of formula IV using
similar condition as described for compounds of formula V as shown in scheme 1.
Compounds of formula XV is synthesized from reaction of compounds of formula XIII and
compounds of formula XIV. The reaction is carried out in the presence of suitable base such
as triethyl amine and suitable solvent such as THF, dioxane and MDC.
Compounds of formula II, VIII and XIII are either commercially available or
synthesized using conventional methods known to one of skill in the art. Some of compounds
of formula VIII are synthesized from appropriate starting material using similar procedure as
described in Modern Drug Synthesis, Edited by Jie Jack Li and Douglas S. Johnson, 2010, pp
131, Published by John Wiley & Sons. Several compounds of formula XIII are synthesized
using the procedure as described in Indian Journal of Chemistry, 47B(1), 97-105 (2008), J.
Heterocyclic Chem., 46, 975-979 (2009) and Chem Ber , 99, 94 (1966).
Schemes 1-3 given herein above provide general method of preparation of
compounds of present invention. One of ordinary skill will recognize to introduce various
substituents such as R, R1 R2, R3, , R9, Ra, R , Rc , P, Q, Y, Z and Z' etc in
appropriately modified starting material containing the various substituents. Alternative to
the given schemes, one of ordinary skill will readily synthesize the compounds according to
the present invention using conventional synthetic organic techniques from suitable starting
material which are either commercially available or may be readily prepared.
It is within the purview of a person skilled in the art that variations in reaction time,
temperature, solvents and/or reagents could increase the yields.
In present specification some general terms are used with their known intended
meaning which are defined herein below:
DMF Dimethyl formamide
BoC tert-butoxycarbonyl
MDC Methylene dichloride
THF Tetrahydrofuran
DIEA N,N-diisopropylethylamine
TFA Trifluoroacetic acid
ESMS Electrospray Mass Spectrometry
ESI Electro spray ionization
APCI Atmospheric pressure chemical ionization
Micro Molar
NM Nano Molar
Mass of compounds prepared according to present invention is measured using Single
quadrupole mass spectrometer (Water ZQ 2000 instrument) using APCI ionization technique
(Electro spray chemical ionization Probe) or Finnigan LXQ, thermo instrument Technique
using either ESI or APCI.
The novel compounds of the present invention were prepared according to the
procedure of the schemes as described herein above, using appropriate materials and are
further exemplified by the following specific examples. The examples are not to be
considered or construed as limiting the scope of the invention set forth.
Examples for preparation of Intermediates:
Example 1
Tert-butyl (7-hydroxy-2,3-dihydro-lH-inden-4-yl)carbamate (Intermediate 1)
To a stirred solution of 7-amino-2,3-dihydro-lH-inden-4-ol (40gm, 161mmol)
(prepared by the procedure as described in US 6203580) and triethyl amine (26.71ml,
192mmol) in ethyl acetate (500ml), di-tert-butylpyrocarbonate (37ml, 161mmol) was added
over a period of 1 h at room temperature. The reaction mixture was further stirred at room
temperature for 1 h. The reaction mixture was quenched by water, stirred and ethyl acetate
layer was separated, dried over sodium sulfate and concentrated under vacuum to get residual
solid. The residue was stirred in hexane (500 ml) for 1 h at room temperature. The solid
appeared, was filtered and dried under vacuum to get 38.0 gm of title compound as solid.
1H-NMR (400 MHz, CDC13) : 7.19 (1H, d), 6.48 (1H, d), 6.11 (1H, s), 5.82 (1H, bs), 2.80
(4H, q), 2.03-2.10 (2H, m), 1.50 (9H, s).
ESMS: 250.08
Example 2
2,2,2-trichloroethyl[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]carbamate
(Intermediate 2)
To a stirred solution of 3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-amine (80gm,
349 mmol) (J. Med. Chem., 2002, 45, 2994-3008) and sodium bicarbonate (80gm, 952.38
mmol) in tetrahydrofuran (500 ml), 2,2,2-trichloroethyl chloroformate (57ml, 420mmol) was
added at 5-10 °C. The reaction mixture was stirred at room temperature for 4 h. The reaction
mixture was poured into water and extracted by ethyl acetate. Ethyl acetate layer was
separated, dried over sodium sulfate and evaporated under vacuum to get crude compound.
The crude compound was suspended in hexane (500 ml), stirred at 0-5 °C and separated solid
was filtered and dried to get 102.0 gm of title compound as solid.
1H-NMR (400 MHz, DMSO-J 6) : 9.90 (1H, s), 7.35 (2H, d), 7.25 (2H, d), 6.26 (1H, s), 4.85
(2H, s), 2.33 (3H, s), 1.27 (9H, s).
ESMS: 403.90, 405.91
Example 3
2,2,2-trichloroethyl{5-tert-butyl-3-[(ethylsulfonyl)amino]-2-methoxyphenyl} carbamate
(Intermediate 3)
Using the similar procedure as described for 2,2,2-trichloroethyl[3-tert-butyl-l-(4-
methylphenyl)-lH-pyrazol-5-yl] carbamate (Intermediate 2) in Example 2, the title compound
was synthesized from N-(3-amino-5-tert-butyl-2-methoxyphenyl)ethanesulfonamide (J. Med.
Chem., 2007, 50, 4016-4026) and 2,2,2 -trichloroethyl chloroformate.
1H-NMR (400 MHz, DMSO-d6) : 9.44 (1H, s), 9.1 1 (1H, s), 7.34 (1H, s), 7.18 (1H, d), 4.93
(2H, s), 3.70 (3H, s), 3.09-3.20 (2H, m), 1.28 (12H, m)
ESMS: 460.95
Using the similar procedure as described for 2,2,2-trichloroethyl[3-tert-butyl-l-(4-
methylphenyl)-lH-pyrazol-5-yl] carbamate (Intermediate 2), 2,2,2-trichloroethyl [3-tertbutyl-
l-(3-chloro-4-hydroxyphenyl)-l H-pyrazol-5-yl]carbamate (Intermediate 4), 2,2,2-
trichloroethyl[3-teri-butyl- 1-(3-chloro-4-methoxyphenyl)- lH-pyrazol-5-yl] carbamate
(Intermediate 5), 2,2,2-trichloroethyl [3-teri-butyl-l-(4-methoxyphenyl)-l H-pyrazol-5-
yl]carbamate (Intermediate 6) and 2,2,2-trichloroethyl [3-tert-butyl-l-(3-chloro-4-
methylphenyl)-lH-pyrazol-5-yl] carbamate (Intermediate 7) were synthesized from
corresponding aminopyrazole compound.
Example 4
Tert-butyl 2-nitro-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate (Intermediate 8)
To a stirred solution of 2-nitro-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (50gm, 271.73
mmol) and triethyl amine (86.57ml, 600mmol) in tetrahydrofuran (500ml), di-tert-butyl
pyrocarbonate (69ml, 300mmol) was added at room temperature. The reaction mixture was
stirred at room temperature for 3 h and concentrated under vacuum. The residue was
dissolved in ethyl acetate and washed by water. Ethyl acetate layer was separated, dried over
Na2S0 4 and concentrated under vacuum to get 52.0 gm of title compound as solid.
Example 5
Tert-butyl 2-(acetylamino)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-carboxylate
(Intermediate 9)
To a stirred solution of tert-butyl 2-nitro-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-
carboxylate (Intermediate 8) (52gm, 183.09mmol) and acetic anhydride (52ml, 520mmol) in
acetic acid (500ml), iron powder (52.08gm, 930mmol) was added at room temperature. The
reaction mixture was stirred at room temperature for 5 h and quenched by water. The reaction
mixture was basified to pH 8-9 by aqueous sodium bicarbonate solution and extracted by
ethyl acetate. Ethyl acetate layer was separated, dried over Na2S0 4 and concentrated under
vacuum to get 45.0 gm of title compound as solid.
Example 6
N-[5-(chloroacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]acetamide (Intermediate
10)
To a stirred solution of tert-butyl 2-(acetylamino)-6,7-dihydrothieno[3,2-c]pyridine-
5(4 H)-carboxylate (Intermediate 9) (45gm, 152.02mmol) in dichloromethane (500ml),
trifluoroacetic acid (58.54ml, 760mmol) was added at room temperature. The reaction
mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated
under vacuum to get 40 g of TFA salt of N-(4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-
yl)acetamide. To a stirred solution of obtained residue of N-(4,5,6,7-tetrahydrothieno[3,2-
c]pyridin-2-yl)acetamide and triethyl amine (65.8ml, 456.08mmol) in dichloromethane (500
ml), chloroacetyl chloride (13.39 ml, 168mmol) was added and the reaction mixture was
stirred at room temperature for 1 h. The reaction mixture was concentrated under vacuum and
water was added to the residue. The solution stirred at room temperature for 15 minute. The
solid thus obtained was filtered and dried under vacuum to get 40.0 gm of title compound as
solid.
ESMS: 273.33, 271.41
Example 7
7-(2-chloroethyl)-3-(5-chloro-2-methoxyphenyl)-5,6,7,8-tetrahydro[l,2,4]triazolo [4,3-
a]pyrazine (Intermediate 11)
tetrahydro[l,2,4]triazolo [4,3-a]pyrazine (88gm, 333.33mmol) and potassium carbonate
(138gm, lOOOmmol) in dimethyl formamide (700ml), 1-bromo-2-chloroethane (138ml,
1659mmol) was added at room temperature. The reaction mixture was stirred at room
temperature for 36 h. The reaction mixture was quenched with water and extracted with
toluene. Toluene layer was separated, dried over sodium sulfate and concentrated under
vacuum. The residue was stirred in 50 ml toluene at room temperature for 30 min. The solid
thus obtained was filtered and dried under vacuum to get 40.0 gm of title compound as solid.
1H-NMR (400 MHz, DMSO-J 6) : 7.58-7.61 (1H, dd), 7.42 (1H, d), 7.24(1H, d), 3.89 (2H,
s), 3.82 (3H, s), 3.77-3.80 (4H, m), 2.91-2.94 (4H, m).
ESMS: 326.91, 328.86
Example 8
4-(2-chloroethyl)-l-(cyclopropylmethyl)piperazin-2-one (Intermediate 12)
Using the similar procedure as described for 7-(2-chloroethyl)-3-(5-chloro-2-
methoxyphenyl)-5,6,7,8-tetrahydro[l,2,4]triazolo [4,3-a]pyrazine (Intermediate 11) in
example 7, the title compound was synthesized from l-(cyclopropylmethyl)piperazin-2-one
and 1-bromo-2-chloro ethane.
1H-NMR (400 MHz, CDC13) : 3.63 (2H, t), 3.48 (2H, t), 3.00-3.32 (4H, m), 2.82-2.85 (4H,
m), 0.89 (1H, m), 0.47-0.56 (2H, m), 0.25-0.31 (2H, m).
ESMS: 217.06, 219.08
Example 9
Tert-butyl(7-{2-[3-(5-chloro-2-methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]py
razin-7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)carbamate (Intermediate 13)
To a stirred solution of 7-(2-chloroethyl)-3-(5-chloro-2-methoxyphenyl)-5,6,7,8-tetra
hydro[l,2,4]triazolo[4,3-a]pyrazine (Intermediate 11) (40gm, 122.32mmol) and tert-butyl(7-
hydroxy-2,3-dihydro-lH-inden-4-yl)carbamate (Intermediate 1) (30.45gm, 122.32mmol) in
acetonitrile, potassium carbonate (50.5gm, 366mmol ) was added at room temperature. The
reaction mixture was stirred at 75-85 °C for 24 h. The reaction mixture was quenched with
water and extracted with toluene. Toluene layer was separated, dried over sodium sulfate
and concentrated under vacuum. The residue was stirred in 50 ml toluene at room
temperature for 1 h. The solid obtained was filtered and dried under vacuum to get 40.0 gm
of title compound as solid.
1H-NMR (400 MHz, DMSO-J 6 ) : 8.46 (IH, s), 7.59 (IH, d), 7.42 (IH, s), 7.23 (2H, d),
6.74 (IH, d), 4.16 (2H, t), 3.95 (2H, s), 3.82 (3H, s), 3.80 (2H, m), 2.97 (4H, m), 2.78 (4H, t),
1.96 (2H, m), 1.44 (9H, s).
ESMS: 540.05
Example 10
Tert-butyl(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-l Hinden-
4-yl)carbamate (Intermediate 14)
Using the similar procedure as described for tert-butyl(7-{2-[3-(5-chloro-2-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden
-4-yl) carbamate (Intermediate 13) in example 9, the title compound was synthesized
from 4-(2-chloroethyl)-l-(cyclo propylmethyl)piperazin-2-one (Intermediate 12) and tertbutyl
7-hydroxy-2,3-dihydro-lH-inden-4-yl) carbamate (Intermediate 1).
1H-NMR (400 MHz, DMSO-J 6) : 8.45 (1H, s), 7.09 (1H, d), 6.70 (1H, d), 4.07 (2H, t), 3.35-
3.36 (2H, m, partially merged with water peak), 3.16- 3.13 (4H, m), 2.74-2.79 (8H, m), 1.91-
1.99 (2H, m), 1.44 (9H, s), 0.90-0.93 (1H, m), 0.37-0.45 (2H, m), 0.17-0.19 (2H, m).
ESMS: 430.09
Example 11
Tert-butyl(7-{2-[2-(acetylamino)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-2-oxo
ethoxy}-2,3-dihydro-lH-inden-4-yl)carbamate (Intermediate 15)
Using the similar procedure as described for tert-butyl(7-{2-[3-(5-chloro-2-methoxy
phenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden -4-
yl)carbamate (Intermediate 13) in example 9, the title compound was synthesized from N-[5-
(chloroacetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]acetamide (Intermediate 10) and
tert-butyl(7-hydroxy-2,3-di hydro- lH-inden-4-yl)carbamate (Intermediate 1).
Example 12
7-{2-[3-(5-chloro-2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-amine (Intermediate 16)
To a stirred solution of tert-butyl(7-{2-[3-(5-chloro-2-methoxyphenyl)-5,6-dihydro
[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)carbamate
(Intermediate 13) (40 gm, 74.07mmol), in dichloromethane (400ml), boron tribromide
(35ml, 370mmol ) was added drop wise over a period of 30 min. at room temperature. The
reaction mixture was stirred at room temperature for 10-12 h. The reaction mixture was
quenched with water. Dichloromethane layer was separated and the pH of aqueous layer was
adjusted to 8-9 by aqueous sodium bicarbonate solution. The solid obtained was filtered and
dried under vacuum to get 25.0 gm of title compound as solid.
1H-NMR (400 MHz, DMSO-J 6 ) : 10.91 (1H, s), 7.40-7.43 (2H, m), 7.03 (1H, d), 6.54 (1H,
d), 6.35 (1H, d), 4.43 (2H, bs), 4.00-4.05 (4H, m), 3.94 (2H, s), 2.98 (2H, m), 2.93 (2H, m),
2.74 (2H, t), 2.63 (2H, t), 1.94-1.98 (2H, m).
ESMS: 426.00
Example 13
4-{2-[(7-amino-2,3-dihydro-lH-inden-4-yl)oxy]ethyl}-l-(cyclopropylmethyl)piperaz -in-
2-one (Intermediate 17
To a stirred solution of tert-butyl(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-l-yl]
ethoxy}-2,3-dihydro-lH-inden-4-yl)carbamate (Intermediate 14) (58gm, 135.19mmol) in
dichloromethane (500ml), trifluoroacetic acid ( 31.2ml, 405mmol) was added at 0°C. The
reaction mixture was stirred at room temperature for 6 h. The reaction mixture was quenched
with water and basified to pH-8 by sodium bicarbonate in water. Dichloromethane layer was
separated, dried over sodium sulfate and concentrated under vacuum and further stirred in diisopropyl
ether. The resultant solid was filtered and dried under vacuum to get 55.0 gm of
title compound as solid.
^-NMR (400 MHz, DMSO-J6 ) : 7.02 (1H, d), 6.85 (1H, d), 4.25 (2H, bs), 3.66 (2H, bs),
3.54 (2H, bs), 3.21-3.29 (6H, m), 2.81-2.87 (4H, m), 2.05 (2H, m), 0.95 (1H, m), 0.45 (2H,
d), 0.22 (2H, bs).
ESMS: 330.12
Example 14
N-(5-{[(7-amino-2,3-dihydro-lH-inden-4-yl)oxy]acetyl}-4,5,6,7-tetrahydrothieno [3,2-
c]pyridin-2-yl)acetamide (Intermediate 18)
Using the similar procedure as described for 4-{2-[(7-amino-2,3-dihydro-lH-inden-4-
yl)oxy]ethyl}-l-(cyclopropylmethyl)piperaz-in-2-one (Intermediate 17), the title compound
was synthesized from tert-butyl(7-{2-[2-(acetylamino)-6,7-dihydrothieno[3,2-c]pyridin-
5(4H)-yl]-2-oxoethoxy}-2,3-dihydro-lH-inden-4-yl)carbamate (Intermediate 15) and
trifluoroacetic acid.
Other intermediate compounds useful for the preparation of compounds of the present
invention can also be prepared in analogous manner by using the synthetic schemes as
described above:
Examples for preparation of compounds according to present invention:
Example 15
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-4-yl]-3-(7-{2-[3-(5-chloro-2-hydroxy
phenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)urea (Compound No. 38)
To a stirred solution of 7-{2-[3-(5-chloro-2-hydroxyphenyl)-5,6-
dihydro[l,2,4]triazolo[ 4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-amine
(Intermediate 16) (25gm, 58.82mmol) and ,-diisopropylethylamine (31.50ml, 176mmol)
in ethyl acetate (250ml), 2,2,2-trichloro ethyl[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-
yl]carbamate (Intermediate 2) (28.28gm, 70mmol) was added at room temperature. The
reaction mixture was refluxed for 8-12 h. The reaction mixture was cooled to room
temperature and the separated solid was filtered, washed with di-isopropyl ether (500ml),
dried under vacuum and crystallized by Ethanol to get 22.0 gm of title compound as white
solid.
^-NMR (400 MHz, DMSO-d6) : 10.91 (1H, s), 8.50 (1H, s), 8.20 (1H, s), 7.51 (1H, d),
7.38-7.43 (4H, m), 7.33 (2H, d), 7.03 (1H, d), 6.75 (1H, d), 6.32 (1H, s), 4.15 (2H, bs), 4.01
(2H, bs), 3.96 (2H, s), 2.98-3.00 (4H, m), 2.80 (2H, t), 2.72 (2H, t), 2.37 (3H, s), 2.00 (2H, t),
1.26 (9H, s)
ESMS: 681.28 (M+)
Example 16
N-(5-tert-butyl-3-{[(7-{2-[4-(cyclopropylmethyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-di
hydro-lH-inden-4-yl)carbamoyl]amino}-2-methoxyphenyl)ethanesulfonamide
(Compound No. 43 )
To a stirred solution of 4-{2-[(7-amino-2,3-dihydro-lH-inden-4-yl)oxy]ethyl}-l-
(cyclo propylmethyl)piperazin-2-one (Intermediate 17) (55gm, 129.13mmol) and N,Ndiisopropyethylamine
(70.33ml, 545mmol) in isopropyl acetate (300ml), 2,2,2-
trichloroethyl {5-tert-butyl-3-[(ethylsulfonyl)amino]-2-methoxyphenyl Jcarbamate
(Intermediate 3) (74.46gm, 161.25mmol) was added at room temperature. The reaction
mixture was refluxed for 8-12 h. The reaction mixture was cooled to room temperature and
the separated solid was filtered, washed with di-isopropyl ether (500ml), dried under vacuum
and crystallized by ethanol to get 50.0 gm of title compound as white solid.
1H-NMR (400 MHz, DMSO-d6) : 9.05 (IH, s), 8.59 (IH, s), 8.43 (IH, s), 8.08 (IH, d), 7.61
(IH, d), 6.95 (IH, d), 6.73 (IH, d), 4.08 (2H, t), 3.71 (3H, s), 3.33 (2H, partially merged with
water signal), 3.10-3.17 (6H, m), 2.74-2.84 (8H, m), 2.02 (2H, m), 1.28 (3H, t), 1.23 (9H, s),
0.94 (IH, m), 0.41-0.46 (2H, m), 0.19 (2H, m).
ESMS: 642.10 (M+l)
Example 17
N-[5-({[7-({[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]carbamoyl}amino)-2,3-
dihydro-lH-inden-4-yl]oxy}acetyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl]
acetamide (Compound No. 52)
To a stirred solution of N-(5-{[(7-amino-2,3-dihydro-lH-inden-4-yl)oxy]acetyl}-
4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl)acetamide (Intermediate 18) (25gm, 64.93mmol)
and ,-diisopro -pylethylamine (33.09ml, 195mmol) in tetrahydrofuran (250 ml), 2,2,2-
trichloroethyl[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-yl]carbamate (Intermediate 2)
(31.51gm, 78mmol) was added. The reaction mixture was refluxed for 8-12 h. The reaction
mixture was cooled to room temperature and quenched with water. The reaction mixture was
extracted by ethyl acetate. Ethyl acetate layer was dried over sodium sulphate and
concentrated under vacuum. The concentrate was stirred with di-isopropyl ether (500ml),
filtered, dried under vacuum and crystallized by ethanol to get 20.0 gm of title compound as
white solid.
1H-NMR (400 MHz, DMSO-J 6) : 11.03 (IH, s), 8.48 (IH, s), 8.19 (IH, s), 7.43 (IH, t),
7.38 (2H, d), 7.33 (2H, d), 6.64 (IH, t), 6.37 (IH, s), 6.32 (IH, s), 4.83 (2H, d), 4.43-4.50
(2H, d), 3.73 (2H, m), 2.65-2.82 (6H, m), 2.37 (3H, s), 1.88-1.91 (5H, m), 1.26 (9H, s).
ESMS: 641.57 (M+l), 639.59 (M-l)
The following representative compounds of the present invention were prepared in
analogous manner by using the synthetic schemes as described above:
Table-1:
Comp. - M (400 MHz, OMSO-d6 ) MASS
No.
m), 6.55 (IH, d), 6.32 (IH, s), 4.98-5.08 (2H, m), 4.74 (2H, s), 3.94- (M-l)
4.19 (4H, m), 2.81 (2H, m), 2.56 (2H, m), 2.32 (3H, s), 1.98-2.00
(2H, m), 1.32 (9H, s)
2 NMR (CDC13) 7.43 (2H, d), 7.29-7.36 (3H, m), 6.63 (IH, m), 6.48 679.64
(IH, m), 6.33 (2H, s), 5.04-5.12 (2H, m), 4.77 (2H, s), 4.08-4.14 (4H, (M+l)
m), 2.85 (2H, m), 2.62 (2H, m), 2.03 (2H, m), 1.34 (9H, s), 1.3 1 (9H,
s)
3 NMR (CDC13) 8.34 (IH, s), 7.92 (IH, m), 7.67 (IH, d), 7.47 (2H, 705.61
d), 7.31 (2H, d), 6.66 (IH, m), 6.46 (IH, s), 5.15 (IH, s), 5.04 (IH, (M+l)
s), 4.80 (2H, s), 4.24 (IH, s), 4.10-4. 13 (2H, m), 2.88 (2H, t), 2.76
(2H, m), 2.58 (5H, m), 2.07 (2H, m), 1.75-1.85 (4H, m), 1.42-1 .48
(3H, m), 1.32 (9H, s)
4 NMR (CDC13) 7.36-7.42 (4H, m), 7.30 (IH, d), 7.24 (IH, m), 623.65
6.58-6.62 (3H, m), 6.35 (IH, s), 5.02-5.09 (2H, m), 4.75 (2H, s), (M+l),
4.13-4.20 (2H, m), 4.06 (2H, m), 2.83 (2H, t), 2.60 (2H, m), 2.01 621 .67
(2H, m), 1.34 (9H, s) (M-l)
5 8.55 (IH, s), 8.21 (IH, s), 7.52-7.58 (5H, m), 7.41-7.47 (3H, m), 661 .56
7.21 (IH, d), 7.10 (IH, t), 6.69 (IH, d), 6.34 (IH, s), 4.85-5.00 (4H, (M+l)
m), 3.77-3.90 (7H, m), 2.82 (2H, t), 2.73 (2H, t), 2.01 (2H, m), 1.27
(9H, s)
Comp. - M (400 MHz, OMSO-d6 ) MASS
No.
8.49 (IH, s), 8.18 (IH, s), 7.49 (IH, d), 7.34-7.38 (4H, m), 6.71 574.36
(IH, d), 6.32 (IH, s), 4.45-4.70 (2H, m), 4.06 (2H, bs), 3.49 (2H, bs), (M+)
3.32 (2H, m, merged with water peak), 3.12 (2H, s), 2.75 (6H, bs),
2.37(3H, s), 1.99 (2H, bs), 1.26 (9H, s), 1.03 (2H, d)
8.55 (IH, s), 8.20 (IH, s), 7.68-7.70 (IH, m), 7.52-7.56 (5H, m), 675(M-1),
7.40-7.47 (3H, m), 7.31 (IH, m), 6.67 (IH, d), 6.34 (IH, s), 5.02- 677.08(M
4.87 (3H, m), 3.90 (3H, bs), 2.81 (2H, t), 2.73 (2H, t), 2.43 (3H, s), +1)
2.00 (2H, t), 1.27 (9H, s), 1.23 (2H, m)
10.53 (IH, s), 8.43 (IH, s), 8.18 (IH, s), 7.56 (IH, t), 7.46 (IH, d), 709.17(M-
7.41 (2H, d), 7.28 (IH, d), 7.21 (IH, d), 7.07-7.12 (2H, m), 6.69 (IH, 1), 7 11
d), 6.28 (IH, s), 4.96-5.00 (2H, d), 4.85-4.92 (2H, m), 3.87-3.90 (3H, (M+l)
m), 3.81 (3H, s), 3.77 (IH, m), 2.82 (2H, t), 2.73 (2H, t), 2.01 (2H, t),
1.25 (9H, s)
8.45 (IH, s), 8.18 (IH, s), 7.54-7.56 (IH, m), 7.46 (2H, m), 7.37- 725.17
7.42 (2H, m), 7.26-7.31 (2H, m), 7.08 (IH, d), 6.67 (IH, d), 6.28 (M-l)
(IH, s), 4.87-5.01 (4H, m), 3.75-3.90 (4H, s), 2.81 (2H, t), 2.73 (2H,
t), 2.43 (3H, s), 2.00 (2H, t), 1.25 (9H, s)
8.49 (IH, s), 8.19 (IH, s), 7.54-7.56 (IH, m), 7.47 (2H, m), 7.32- 691 .25
7.39 (6H, m), 6.67 (lH,d), 6.32 (IH, s), 4.87-5.01 (4H, m), 3.75-3.90 (M+l)
(4H, m), 2.80 (2H, t), 2.72 (2H, t), 2.43 (3H, s), 2.37 (3H, s), 2.00
(2H, t), 1.26 (9H, s)
8.55 (IH, s), 8.20 (IH, s), 7.52-7.44 (10H, m), 6.68 (IH, m), 6.34 774(M-1),
(IH, s), 4.88-5.02 (4H, m), 3.76-3.90 (4H, m), 3.5 1 (6H, bs), 3.05 776.42(M
(2H, m), 2.81 (2H, t), 2.72 (2H, t), 2.33 (4H, bs), 2.00 (2H, t), 1.27 +1)
(9H, s)
8.50 (IH, s), 8.19 (IH, s), 7.5 1 (IH, d), 7.39 (2H, d), 7.32 (2H, d), 585.48
6.71 (IH, d), 6.33 (IH, s), 4.06 (2H, t), 3.33-3.35 (2H, m), 3.13-3.16 (M+l)
(4H, m), 2.72-2.79 (8H, m), 2.36 (3H,s), 1.97-2.03 (2H, m), 1.27
(9H, s), 0.93 (IH, m), 0.43 (2H, d), 0.18 (2H, d)
8.50 (IH, s), 8.20 (IH, s), 7.50-7.57 (2H, m), 7.45 (IH, d), 7.38- 675.16
7.40 (3H, m), 7.28-7.34 (3H, m), 6.75 (IH, d), 6.33 (IH, s), 4.15 (M-l)
(2H, t), 3.97 (2H, s), 3.77 (2H, t), 2.98 (4H, bs), 2.79 (2H, t), 2.72
(2H, t), 2.43 (3H, s), 2.37 (3H, s), 2.00 (2H, m), 1.27 (9H, s)
8.50 (IH, s), 8.20 (IH, s), 7.50-7.56 (2H, m), 7.38-7.40 (3H, m), 661 .22
7.33 (2H, d), 7.20 (IH, d), 7.09 (IH, t), 6.76 (IH, d), 6.33 (IH, s), (M+l),
4.16 (2H, t), 3.95 (2H, s), 3.82 (3H, s), 3.78 (2H, t), 2.95-2.99 (4H, 659.15
m), 2.80 (2H, t), 2.73 (2H, t), 2.37 (3H, s), 1.99-2.04 (2H, m), 1.27 (M-l)
(9H, s)
10.71 (IH, bs), 8.50 (IH, s), 8.19 (IH, s), 7.50 (IH, d), 7.46 (IH, 647.03
d), 7.32-7.40 (5H, m), 7.01 (IH, d), 6.94 (IH, t), 6.75 (IH, d), 6.32 (M+l)
(IH, s), 4.16 (2H, t), 4.03 (2H, t), 3.81 (2H, s), 2.98-3.02 (4H, m),
2.80 (2H, t), 2.72 (2H, t), 2.37 (3H, s), 1.98-2.04 (2H, m), 1.26 (9H,
Comp. - M (400 MHz, OMSO-d6 ) MASS
No.
s)
8.48 (1H, s), 8.18 (1H, s), 7.49 (1H, d), 7.38 (2H, m),7.33 (4H, m), 621 .44
7.27 (1H, d), 7.22 (2H, d), 6.71 (1H, d), 6.32 (1H, s), 4.51 (2H, s), (M+l)
4.06 (2H, t), 3.23 (2H, s), 3.18 (2H, t), 2.69-2.76 (8H, m), 2.37 (3H,
s), 1.98 (2H, m), 1.26 (9H, s)
8.44 (1H, s), 8.17 (1H, s), 7.49 (1H, d), 7.40 (2H, d), 7.07 (2H, d), 601 .48
6.72 (1H, d), 6.30 (1H, s), 4.07 (2H, m), 3.81 (3H, s), 3.33 (2H, (M+l)
partially merged with water peak), 3.13-3.17 (4H, m), 2.72-2.77 (8H,
m), 1.99-2.01 (2H, m), 1.26 (9H, s), 0.93 (1H, m), 0.43 (2H, d), 0.20
(2H, m)
9.77 (1H, s), 8.40 (1H, s), 8.20 (1H, s), 7.50 (1H, d), 7.26 (2H, d), 587.43
6.88 (2H, d), 6.72 (1H, d), 6.29 (1H, s), 4.07 (2H, bs), 3.33-3.36 (2H, (M+l)
m, partially merged with water peak), 3.13-3.17 (4H, m), 2.70-2.77
(8H, m), 1.99 (2H, t), 1.25 (9H, s), 0.93 (1H, m), 0.43 (2H, d), 0.19
(2H, d)
NMR (DMSO-d6 + D20) 7.46-7.53 (3H, m), 7.34-7.39 (7H, m), 607.46
6.81 (1H, d), 6.33 (1H, s), 4.38 (2H, bs), 4.20 (2H, s), 3.96 (2H, bs), (M+l)
3.73 (4H, m, partially merged with water signal), 2.85-2.90 (2H, m),
2.73 (2H, m), 2.37 (3H, s), 1.99-2.04 (2H, m), 1.27 (9H, s)
8.50 (1H, s), 8.19 (1H, s), 7.70 (1H, m), 7.49-7.51 (2H, d), 7.39 760.35
(2H, d), 7.33 (2H, d), 7.20 (1H, d), 7.07 (1H, t), 6.74 (1H, d), 6.32 (M+)
(1H, s), 4.13-4.14 (4H, m), 3.94 (4H, bs), 3.50 (4H, bs), 2.98 (4H,
bs), 2.79 (2H, t), 2.72 (2H, t), 2.58 (2H, t), 2.37 (3H, s), 2.33 (4H,
m), 2.00 (2H, m), 1.26 (9H, s)
8.50 (1H, s), 8.19 (1H, s), 7.49 (1H, d), 7.39 (2H, d), 7.33 (2H, d), 613.51
6.71 (1H, d), 6.32 (1H, s), 4.07 (2H, bs), 3.27 (2H, t), 3.22 (2H, d), (M+l)
3.13 (2H, bs), 2.70-2.77 (8H, m), 2.37 (3H, s), 2.13-2.19 (1H, m),
1.97-2.01 (2H, m), 1.59 (4H, m), 1.47 (2H, m), 1.26 (9H, s), 1.14-
1.16 (2H, m)
8.49 (1H, s), 8.18 (1H, s), 7.49 (1H, d), 7.38 (2H, d), 7.33 (2H, d), 599.55
6.71 (1H, d), 6.32 (1H, s), 4.00-4.07 (2H, m), 3.22 (2H, t), 3.1 1 (2H, (M+l)
s), 2.70-2.78 (8H, m), 2.37 (3H, s), 1.95-2.01 (5H, m), 1.77-1 .85
(2H, m), 1.65-1.71 (2H, m), 1.26 (9H, s), 1.17 (2H, t)
8.53 (1H, s), 8.20 (1H, s), 7.50-7.56 (2H, m), 7.35-7.42 (5H, m), 675.67(M
7.19 (1H, d), 7.08 (1H, t), 6.75 (1H, d), 6.33 (1H, s), 4.16 (2H, t), +1)
3.94 (2H, s), 3.81 (3H, s), 3.77 (2H, t), 2.96 (4H, m), 2.79 (2H, t),
2.64-2.74 (4H, m), 2.00 (2H, m), 1.26 (9H, s), 1.22 (3H, t)
10.55 (1H, s), 8.44 (1H, s), 8.17 (1H, s), 7.54 (1H, t), 7.43-7.47 713.43
(3H, m), 7.38 (1H, d), 7.26-7.31 (2H, m), 7.08 (1H, d), 6.75 (1H, d), (M+)
6.29 (1H, s), 4.15 (2H, t), 3.96 (2H, s), 3.76 (2H, t), 2.98 (4H, m),
2.79 (2H, t), 2.73 (2H, t), 2.50 (3H, s), 1.97-2.03 (2H, m), 1.25 (9H,
Comp. - M (400 MHz, OMSO-d6 ) MASS
No.
s)
25 10.54 (1H, s), 8.43 (1H, s), 8.17 (1H, s), 7.54 (1H, t), 7.45-7.47 697.34
(2H, m), 7.38 (1H, d), 7.28 (1H, m), 7.19 (1H, d), 7.07-7.09 (2H, m), (M+)
6.75 (1H, d), 6.29 (1H, s), 4.16 (2H, t), 3.94 (2H, s), 3.81 (3H, s),
3.77 (2H, m), 2.96 (4H, m), 2.80 (2H, t), 2.73 (2H, t), 2.00 (2H, m),
1.25 (9H, s)
26 10.71 (1H, bs), 8.44 (1H, s), 8.17 (1H, s), 7.45-7.47 (3H, m), 7.36 683.39
(1H, t), 7.28 (lH,dd), 7.08 (1H, d), 7.01 (1H, d), 6.94 (1H, t), 6.75 (M+)
(1H, d), 6.29 (1H, s), 4.15 (2H, t), 4.02 (2H, t), 3.96 (2H, s), 2.98-
3.01 (4H, m), 2.80 (2H, t), 2.73 (2H, t), 2.00 (2H, m), 1.25 (9H, s)
10.54 (1H, s), 8.43 (1H, s), 8.17 (1H, s), 7.49-7.51 (1H, m), 7.45 725.43(M
(2H, bs), 7.37 (1H, d), 7.27 (1H, d), 7.18 (1H, d), 7.08 (2H, m), 6.75 +)
(1H, d), 6.29 (1H, s), 4.15 (2H, m), 3.95-3.99 (4H, m), 3.80 (2H, m),
2.97 (4H, bs), 2.73-2.79 (4H, m), 1.99 (2H, t), 1.64 (2H, q), 1.25
(9H, s), 0.85 (3H, t)
NMR (DMSO-d6 + D20) 7.39-7.45 (5H, m), 6.75 (1H, d), 6.35 599.59
(1H, s), 4.02 (2H, partially merged with water signal), 3.42 (2H, bs), (M+l)
3.22 (2H, d), 3.06 (2H, s), 2.80-2.82 (2H, t), 2.71-2.75 (4H, m), 2.55-
2.59 (2H, partially merged with solvent signal), 2.42 (3H, s), 2.04
(2H, t), 1.91 (2H, t), 1.32 (9H, s), 0.99 (1H, bs), 0.50 (2H, d), 0.26
(2H, d)
8.50 (1H, s), 8.19 (1H, s), 7.63 (1H, d), 7.53 (2H, dd), 7.39 (2H, d), 681 .53
7.33 (2H, d), 7.00 (1H, t), 6.75 (1H, d), 6.32 (1H, s), 4.22 (2H, t), (M+),
4.16 (2H, t), 4.02 (2H, s), 3.06 (2H, t), 3.00 (2H, t), 2.80 (2H, t), 2.72 683.51
(2H, t), 2.37 (3H, s), 2.00 (2H, t), 1.26 (9H, s) (M+2)
8.49 (1H, s), 8.19 (1H, s), 7.50 (2H, d), 7.34-7.40 (5H, m), 7.19 691 .22
(1H, d), 7.07 (1H, t), 6.75 (1H, d), 6.32 (1H, s), 4.91 (1H, bs), 4.15 (M+l)
(2H, bs), 4.08 (2H, bs), 3.90-3.95 (4H, m), 3.66 (2H, bs), 2.97 (4H,
bs), 2.79 (2H, t), 2.72 (2H, t), 2.37 (3H, s), 2.00 (2H, m), 1.26 (9H,
s).
10.71(1H, s), 8.50 (1H, s), 8.20 (1H, s), 7.74 (1H, s), 7.53 (2H, dd), 681 .53
7.36 (4H,dd), 7.09 (1H, d), 6.75 (1H, d), 6.32 (1H, s), 4.11-4.15 (4H, (M+),
m), 3.94 (2H, s), 2.98-3.00 (4H, m), 2.80 (2H, t), 2.73 (2H, t), 2.37 679.58
(3H, s), 1.98-2.02 (2H, m), 1.26 (9H, s) (M-2)
32 8.48 (1H, s), 8.18 (1H, s), 7.50 (2H, m), 7.32-7.39 (5H, m), 7.18 702.84
(1H, d), 7.08 (1H, t), 6.74 (1H, s), 6.32 (1H, s), 4.15 (2H, t), 4.02 (M+)
(2H, t), 3.95 (2H, s), 3.80 (2H, t), 2.98 (4H, t), 2.79 (2H, t), 2.72 (2H,
t), 2.37 (3H, s), 1.99 (2H, t), 1.61 (2H, t), 1.30 (2H, m), 1.26 (9H, s),
0.83 (3H, t)
33 8.49 (1H, s), 8.19 (1H, s), 7.49-7.53 (3H, m), 7.39-7.32 (6H, m), 705.67
6.75 (1H, d), 6.32 (1H, s), 4.15 (2H, t), 3.97 (2H, s), 3.75 (2H, t), (M+l)
2.98 (4H, bs), 2.88 (2H, t), 2.79 (2H, t), 2.72 (2H, t), 2.37 (3H, s),
1.98-2.01(2H, m), 1.49-1 .54 (2H, m), 1.26 (9H, s), 0.90 (3H, t)
8.54 (IH, s), 8.23 (IH, s), 7.61 (2H, d), 7.5 1 (IH, d), 7.39 (2H, d), 647.17
7.33 (2H, d), 6.93 (2H, d), 6.76 (IH, d), 6.32 (IH, s), 4.20-4.14 (6H, (M+)
m), 3.15 (4H, d), 2.81 (2H, t), 2.73 (2H, t), 2.37 (3H, s), 2.01 (2H,
m),1.26 (9H, s)
8.45 (IH, s), 8.18 (IH, s), 7.52 (2H, m), 7.46 (2H, d), 7.38 (IH, d), 741 .06
7.31-7.33 (IH, m), 7.27 (IH, dd), 7.07 (IH, d), 6.75 (IH, d), 6.29 (M+l)
(IH, s), 4.15 (2H, t), 3.97 (2H, s), 3.75 (2H, t), 2.98 (4H, bs), 2.88
(2H, t), 2.79 (2H, t), 2.72 (2H, t), 1.99 (2H, m), 1.49-1 .54 (2H, m),
1.25 (9H, s), 0.90 (3H, t)
9.73 (IH, s), 8.49 (IH, s), 8.19 (IH, s), 7.5 1 (IH, d), 7.39 (2H, d), 647.12
7.29-7.34 (3H, m), 7.17 (2H, d), 6.89 (IH, d), 6.75 (IH, d), 6.32 (IH, (M+l)
s), 4.16 (2H, t), 4.11 (2H, t), 3.95 (2H, s), 2.98-3.01 (4H, m), 2.80
(2H, t), 2.72 (2H, t), 2.37 (3H, s), 2.00 (2H, t), 1.26 (9H, s)
10.84 (IH, s), 9.79 (IH, s), 8.49 (IH, s), 8.18 (IH, s), 7.50 (IH, d), 663.16
7.39 (2H, d), 7.29-7.34 (3H, m), 6.75 (IH, d), 6.42 (IH, s), 6.36 (IH, (M+l)
d), 6.32 (IH, s), 4.15 (2H, t), 4.03 (2H, s), 3.93 (2H, s), 2.97-3.00
(4H, m), 2.80 (2H, t), 2.72 (2H, t), 2.37 (3H, s), 2.00 (2H, m), 1.26
(9H, s)
9.07 (IH, s), 8.59 (IH, s), 8.44 (IH, s), 8.10 (IH, d), 7.61 (IH, d), 628.42
6.96 (IH, d), 6.74 (IH, d), 4.08 (2H, t), 3.71 (3H, s), 3.36 (2H, t), (M+l)
3.16 (2H, d), 3.14 (2H, s), 3.06 (3H, s), 2.75-2.89 (8H, m), 1.98-2.07
(2H, m), 1.24 (9H, s), 0.94 (IH, m), 0.41-0.46 (2H, q), 0.19-0.21
(2H, q)
9.09 (IH, s), 8.61 (IH, s), 8.46 (IH, s), 8.10 (IH, s), 7.63 (IH, d), 690.44
7.46 (IH, d), 7.36 (IH, t), 7.01 (2H, d), 6.92-6.96 (2H, m), 6.77 (IH, (M+l)
d), 4.17 (2H, bs), 4.04 (2H, bs), 3.97 (2H, s), 3.71 (3H, s), 3.06 (3H,
s), 3.00 (4H, m), 2.82 (4H, t), 2.04 (2H, m), 1.24 (9H, s)
NMR (DMSO-d6 + D20) 8.06 (IH, s), 7.60 (IH, d), 7.02 (IH, s), 642.64
6.77 (IH, d), 4.03 (2H, m), 3.76 (3H, bs, partially merged with water (M+l)
peak), 3.42 (2H, s), 3.22 (2H, d), 3.06 (5H, m), 2.86 (4H, m), 2.71
(2H, bs), 2.57 (2H, partially merged with solvent peak), 2.08 (2H, t),
1.92 (2H, t), 1.28 (9H, s), 0.99 (IH, m), 0.49 (2H, d), 0.24 (2H, d)
9.07 (IH, s), 8.60 (IH, s), 8.45 (IH, s), 8.10 (IH, s), 7.62 (IH, d), 748.13
7.52 (2H, d), 7.39-7.32 (2H, m), 6.96 (IH, s), 6.76 (IH, d), 4.16 (2H, (M+l)
bs), 3.98 (2H, s), 3.75 (2H,bs), 3.71 (3H, s), 3.06 (3H, s), 2.99 (4H,
bs), 2.88 (2H, t), 2.82 (4H, m), 2.03 (2H, m), 1.49-1 .55 (2H, m), 1.24
(9H, s), 0.90 (3H, t)
NMR (DMSO-d6 + D20) 8.06 (IH, s), 7.59 (IH, d), 7.02 (IH, s), 630.16
6.80 (IH, d), 4.13 (2H, bs), 3.76 (3H, s), 3.31 (4H, bs), 3.20 (2H, s), (M+l)
3.08 (3H, s), 2.83-2.87 (8H, m), 2.04-2.10 (2H, m), 1.48-1 .51 (2H,
m), 1.29 (11H, m), 0.92 (3H, t)
9.06 (IH, s), 8.60 (IH, s), 8.44 (IH, s), 8.09 (IH, s), 7.63 (IH, d), 734.20
7.54 (IH, t), 7.45 (IH, d), 7.38 (IH, d), 7.29 (IH, t), 6.96 (IH, s), (M+)
6.76 (IH, d), 4.16 (2H, t), 3.97 (2H, s), 3.76 (2H, t), 3.71 (3H,s), 3.13
(2H, q), 2.99 (4H, bs), 2.82 (4H, bs), 2.42 (3H, s), 1.99-2.05 (2H, m),
1.28 (3H, t), 1.23 (9H, s)
7.63 (IH, d), 7.31 (IH, t), 7.17 (2H, s), 6.96 (IH, s), 6.90 (IH, d), (M+l)
6.77 (IH, d), 4.17- 4.12 (4H, m), 3.97 (2H, s), 3.71 (3H, s), 3.06 (3H,
s), 3.01 (4H, m), 2.83 (4H, m), 2.04 (2H, t), 1.26 (9H, s)
47 9.08 (IH, s), 8.60 (IH, s), 8.45 (IH, s), 8.10 (IH, s), 7.71 (2H, d), 750.27
7.63 (IH, d), 7.45 (2H, d), 6.96 (IH, s), 6.77 (IH, d), 5.00 (IH, bs), (M+l)
4.14-4.17 (4H, m), 3.97 (2H, s), 3.71 (3H, s), 3.61 (2H, bs), 3.1 1
(2H, t), 3.06 (3H, s), 3.02 (4H, m), 2.82 (4H, m), 2.08 (2H, m), 1.24
(9H, s)
48 10.90 (IH, s), 9.08 (IH, s), 8.60 (IH, s), 8.45 (IH, s), 8.10 (IH, s), 724.20
7.62 (IH, d), 7.40-7.44 (2H, m), 7.03 (IH, d), 6.96 (IH, s), 6.77 (IH, (M+)
d), 4.17 (2H, bs), 4.01 (2H, bs), 3.97 (2H, s), 3.71 (3H, s), 3.06 (3H,
s), 3.00 (4H, m), 2.82 (4H, t), 2.04 (2H, m), 1.24 (9H, s)
49 9.87 (IH, s), 9.05 (IH, s), 8.60 (IH, s), 8.46 (IH, s), 8.08 (IH, d), 720.19
7.62 (IH, d), 7.31 (IH, d), 6.95 (IH, d), 6.77 (IH, d), 6.44 (IH, s), (M+l)
6.38 (IH, dd), 4.18 (2H, t), 4.06 (2H, t), 4.01 (2H, bs), 3.71 (3H, s),
3.13 (2H, q), 3.02-3.06 (4H, m), 2.83 (4H, t), 2.04 (2H, m), 1.28 (3H,
t), 1.23 (9H, s)
50 9.05 (IH, bs), 8.60 (IH, s), 8.45 (IH, s), 8.09 (IH, s), 7.62 (IH, d), 762.05
7.52 (2H, d), 7.38 (IH, d), 7.30-7.33 (IH, m), 6.95 (IH, s), 6.76 (IH, (M+l)
d), 4.16 (2H, t), 3.98 (2H, s), 3.75 (2H, t), 3.71 (3H, s), 3.13 (2H, q),
2.99 (4H, bs), 2.88 (2H, t), 2.81-2.82 (4H, m), 2.03 (2H, t), 1.49-1 .55
(2H, m), 1.28 (3H, t), 1.23 (9H, s), 0.90 (3H, t)
51 10.91 (IH, bs), 9.06 (IH, bs), 8.59 (IH, s), 8.44 (IH, s), 8.08 (IH, 738.08
s), 7.62 (IH, d), 7.40-7.43 (2H, m), 7.03 (IH, d), 6.95 (IH, s), 6.77 (M+)
(IH, d), 4.17 (2H, bs), 4.02 (2H, bs), 3.97 (2H, s), 3.71 (3H, s), 3.13
(2H, q), 3.00 (4H, m), 2.82 (4H, t), 2.04 (2H, m), 1.28 (3H, t), 1.23
(9H, s)
53 (CDC13) 7.41 (IH, m), 7.29-7.34 (IH, m), 7.08-7.13 (IH, m), 6.88 687.62
(IH, d), 6.49-6.5 1 (IH, m), 6.3 1(1H, s), 5.05 (IH, s), 4.91(1H, s), (M+)
4.72 (2H, m), 4.13-4.22 (2H, m), 4.04 (2H, m), 3.83 (3H, s), 2.77
(2H, t), 2.52-2.54 (2H, m), 1.94-1 .95 (2H, m), 1.29 (9H, s),
54 (CDC13) 11.42-1 1.48 (IH, m), 7.29 (2H, m), 7.21-7.23 (IH, m), 739.59
7.16 (2H, m), 6.45-6.51 (IH, m), 6.39 (IH, d), 4.68 (2H, s), 4.59- (M+l)
4.61 (2H, m), 4.33-4.38 (2H, q), 3.73-3.76 (2H, m), 2.85-2.98 (4H,
m), 2.46-2.54 (2H, m), 2.34 (3H, s), 1.93-1.97 (2H, m), 1.68 (IH, m),
1.37-1.42 (3H, m), 1.33 (9H, s), 1.16 (2H, m),.0.95-.0.97 (2H, m),
55 11.03 (IH, s), 8.56 (IH, s), 8.20 (IH, s), 7.36-7.44 (4H, m), 6.66 709.65
(IH, m), 6.37 (IH, s), 6.32 (IH, s), 4.82-4.89 (2H, m), 4.43-4.50 (2H, (M+l)
m), 3.73 (2H, bs), 2.57-2.82 (8H, m), 2.02 (6H, m), 1.80-1.82 (4H,
m), 1.37-1.46 (4H, m), 1.25 (9H, s)
56 (CDC13) 7.45 (IH, s), 7.26 (IH, m, merged with solvent peak), 671 .57
6.65 (IH, m), 6.40 (2H, m), 6.35 (IH, s), 5.05-5.12 (2H, m), 4.78 (M+l)
(2H, s), 4.15 (2H, m), 4.09 (2H, m), 2.85 (2H, t), 2.66 (2H, m), 2.38
(3H, s), 2.04 (2H, m), 1.33 (9H, s),
57 (CDC13) 7.60-7.61 (2H, m), 7.50 (3H, m), 7.29 (IH, m), 7.15 (2H, 643.61
d), 6.84-6.90 (2H, m), 6.61 (IH, d), 6.33 (IH, s), 4.98-5.08 (2H, m), (M-l)
4.76-4.79 (2H, m), 4.03-4.13 (2H, m), 3.97-3.98 (2H, m), 2.84 (2H,
t), 2.54-2.65 (2H, m), 2.32 (3H, s), 1.93-1 .96 (2H, m), 1.33 (9H, s)
Comp. - M (400 MHz, OMSO-d6 ) MASS
No.
58 8.55 (IH, s), 8.20 (IH, s), 7.79 (IH, s), 7.68 (IH, m), 7.53-7.52 695.17
(4H, m), 7.45 (IH, d), 7.40 (IH, m), 7.32-7.34 (IH, m), 6.70 (IH, d), (M+)
6.34 (IH, s), 5.00 (IH, s), 4.95 (2H, s), 4.86 (IH, s), 4.25 (IH, bs),
4.10 (IH, bs), 3.92-3.93 (5H, m), 2.82-2.84 (2H, m), 2.73 (2H, m),
2.01 (2H, m), 1.27 (9H, s)
59 8.49 (IH, s), 8.18 (IH, s), 7.49 (IH, d), 7.32-7.39 (4H, dd), 6.71 573.42
(IH, d), 6.32 (IH, s), 4.06 (2H, t), 3.20-3.26 (4H, m), 3.12 (2H, s), (M+l)
2.70-2.76 (8H, m), 2.37 (3H, s), 1.99 (2H, m), 1.44-1 .50 (2H, m),
1.26 (9H, s), 0.81 (3H, t)
60 8.5 1 (IH, s), 8.14 (IH, s), 7.53-7.57 (2H, m), 7.46 (IH, d), 7.36 589.45
(2H, t), 6.71 (IH, d), 6.32 (IH, s), 4.07 (2H, t), 3.35 (2H, m, merged (M+l)
with water signal), 3.16 (2H, d), 3.13 (2H, s), 2.63-2.79 (8H, m),
1.99 (2H, m), 1.24 (9H, s), 0.93 (IH, m), 0.43 (2H, d), 0.19 (2H, m).
6 1 8.54 (IH, s), 8.18 (IH, s), 7.47-7.53 (5H, m), 7.31 (IH, m), 6.72 571 .43
(IH, m), 6.34 (IH, s), 4.07 (2H, t), 3.33 (2H, merged with water (M+l)
signal), 3.13-3.17 (4H, m), 2.70-2.79 (8H, m), 1.97-2.01 (2H, m),
1.27 (9H, s), 0.93 (IH, m), 0.43 (2H, d), 0.20 (2H, d)
62 8.28 (IH, s), 8.13 (IH, s), 7.48 (IH, d), 7.42 (2H, m), 7.32-7.37 583.45
(2H, m), 6.71 (IH, d), 6.32 (IH, s), 4.02-4.06 (2H, m), 3.33 (2H, (M-l)
merged with water signal), 3.13-3. 17 (4H, m), 2.76 (6H, m), 2.68
(2H, t), 2.02 (3H, s), 1.95-1.99 (2H, m), 1.25 (9H, s), 0.93 (IH, m),
0.43 (2H, d), 0.19 (2H, d)
63 10.83 (IH, s),10.54 (IH, s), 9.79 (IH, s), 8.44 (IH, s), 8.18 (IH, s), 699.15
7.45 (2H, m), 7.27-7.31 (2H, m), 7.08 (IH, d), 6.75(1H, d), 6.42 (IH, (M+)
s), 6.36 (IH, d), 6.29 (IH, s), 4.15 (2H, t), 4.03 (2H, s), 3.93 (2H, s),
2.97-3.00 (4H, m), 2.80 (2H, t), 2.73 (2H, t), 2.00 (2H, m), 1.25 (9H,
s)
64 9.50 (IH, s), 8.48 (2H, d), 8.01 (IH, s), 7.59 (2H, d), 6.74 (IH, d), 618.21
4.08 (2H, t), 3.68 (3H, s), 3.16 (4H, t), 2.80-2.83 (10H, m), 2.54 (3H, (M+l)
partially merged with solvent peak), 2.03-2.05 (4H, m), 1.22 (9H, s),
0.94 (IH, m), 0.43 (2H,m), 0.19 (2H,m)
65 10.54 (IH, s), 8.43 (IH, s), 8.16 (IH, s), 7.44-7.46 (2H, m), 7.27 673.1 1(M
(IH, d), 7.08 (IH, d), 6.74 (IH, d), 6.29 (IH, s), 4.13(2H, t), 3.91 +)
(2H, t), 3.82 (2H, s), 2.93-2.97 (4H, m), 2.67-2.80 (5H, m), 1.99
(2H, m), 1.86 (2H, d), 1.77 (2H, d), 1.66-1.69 (IH, m), 1.48 (2H, q),
1.33-1.35 (3H, m), 1.23 (9H, s)
66 8.83 (IH, s), 8.38 (IH, s), 7.44(1H, s), 7.38 (2H, d), 7.30 (2H, d), 695.05
7.19 (IH, s), 7.13 (IH, m), 6.67 (IH, m), 6.32 (IH, s), 4.02 (2H, s), (M+)
3.94 (2H, s), 3.86 (2H, s), 2.85-2.93 (6H, m), 2.63 (2H, m), 2.35 (3H,
s), 2.15 (3H, s), 1.95 (2H, t), 1.26 (9H, s)
67 8.55 (IH, s), 8.23 (IH, s), 8.12(1H, d), 8.05 (IH, d), 7.86 (IH, d), 681 .17
7.73 (IH, d), 7.63-7.74 (IH, t), 7.55-7.60 (2H, m), 7.58 (IH, d), (M+l)
7.40(2H, d), 7.32 (2H, d), 6.75 (IH, d), 6.32 (IH, s), 4.16 (2H, t),
4.04 (2H, s), 3.80 (2H, t), 2.99-3.00 (4H, m), 2.79 (2H, t), 2.72 (2H,
t), 2.29 (3H, s), 1.99 (2H, t), 1.26 (9H, s).
8.50 (IH, s), 8.19 (IH, s), 7.50 (IH, d), 7.39 (2H, d), 7.32 (2H, d), 637.19
6.73 (IH, d), 6.32 (IH, s), 4.13(2H, t), 3.91 (2H, t), 3.81 (2H, s), (M+l)
3.60 (3H, m), 2.93-2.97 (4H, m), 2.67-2.80 (5H, m), 2.37 (3H, s),
1.99 (2H, quintet), 1.86 (2H, d), 1.67 (IH, d), 1.42-1 .50 (2H, m),
1.32-1.38 (2H, m), 1.26 (9H, s)
Comp. - M (400 MHz, OMSO-d6 ) MASS
69 8.49 (1H, s), 8.19 (1H, s), 7.74(1H, d), 7.62 (1H, d), 7.51 (1H, d), 683.37
7.32-7.44 (6H, m), 6.76 (1H, d), 6.32 (1H, s), 4.36 (2H, t), 4.17(2H, (M-l)
t), 4.00 (2H, s), 3.09 (2H, t), 3.00 (2H, t), 2.81 (2H, t), 2.73 (2H, t),
2.55 (3H, s), 2.37 (3H, s), 2.00 (2H, t), 1.26 (9H, s).
70 8.51 (1H, s), 8.25 (1H, s), 7.49 (1H, d), 6.79 (2H, s), 6.72 (1H, d), 661 .20
6.35 (1H, s), 4.07 (2H, t), 3.81 (6H, s), 3.71 (3H, s), 3.35 (2H, (M+l)
merged with water signal), 3.16 (2H, d), 3.13 (2H, s), 2.70-2.79 (8H,
m), 1.99 (2H, m), 1.27 (9H, s), 0.93 (1H, m), 0.41-0.45 (2H, q), 0.14-
0.21 (2H, q).
7 1 10.33 (1H, s), 8.56 (1H, s), 8.27 (1H, s), 7.55 (1H, d), 7.40 (2H, d), 584.97
7.33 (1H, d), 6.78 (1H, d), 6.33 (1H, s), 4.33 (2H, bs), 4.04 (2H, bs), (M+)
3.58-3.63 (4H, m), 2.83 (2H, t), 2.74 (2H, t), 2.37 (3H, s), 2.36 (7H,
s), 2.02 (2H, t), 1.27 (9H, s), 0.97 (1H, m), 0.47 (2H, d), 0.24 (2H, d).
72 9.08 (1H, s), 8.60 (1H, s), 8.45 (1H, s), 8.10 (1H, s), 7.62 (1H, d), 680.10
6.96 (1H, d), 6.75 (1H, d), 4.14 (2H, t), 3.92 (2H, t), 3.83 (2H, s), (M+l)
3.71(3H, s), 3.06 (3H, s), 2.94-2.98 (4H, m), 2.81-2.82 (4H, q), 2.70
(1H, m), 2.03 (2H, m), 1.86 (2H, d), 1.78 (2H, d), 1.65 (1H, m), 1.45-
1.51 (2H, q), 1.28-1.35 (3H, m), 1.24 (9H, s).
73 10.9 (1H, s), 9.10 (1H, s), 8.65(1H, s), 8.45 (1H, s), 8.09 (1H, s), 737.96
7.56 (1H, s), 7.41-7.44 (2H, m), 7.03 (1H, d), 6.96 (1H, s), 3.96-4.02 (M+)
(6H, m), 3.71 (3H, s), 3.06 (3H, s), 3.00 (2H, t), 2.91-2.94 (4H, m),
2.78 (2H, t), 2.20 (3H, s), 2.04 (2H, m), 1.24 (9H, s).
74 9.07 (1H, s), 8.60 (1H, s), 8.45(1H, s), 8.10-8.14 (2H, m), 8.05 (1H, 724.07
d), 7.86 (1H, d), 7.74 (1H, d), 7.59-7.67 (4H, m), 6.96 (1H, s), (M+l)
6.77(1H, d), 4.18 (2H, t), 4.05 (2H, s), 3.81 (2H, t), 3.71 (3H, s), 3.06
(3H, s), 3.02 (4H, m), 2.82 (4H, t), 2.03 (2H, t), 1.24 (9H, s).
Pharmaceutical compositions
In another embodiment present invention provides a pharmaceutical composition
comprising a therapeutically effective amount of one or more of a compound of formula (I).
While it is possible to administer therapeutically effective quantity of compounds of formula
(I) either individually or in combination, directly without any formulation, it is common
practice to administer the compounds in the form of pharmaceutical dosage forms comprising
pharmaceutically acceptable excipient(s)/adjuvant(s)/carrier(s) and at least one active
ingredient. These dosage forms may be administered by a variety of routes including oral,
topical, transdermal, subcutaneous, intramuscular, intravenous, intraperitoneal, intranasal,
pulmonary etc.
Oral compositions may be in the form of solid or liquid dosage form. Solid dosage
form may comprise pellets, pouches, sachets or discrete units such as tablets, multi
particulate units, capsules (soft & hard gelatin) etc. Liquid dosage forms may be in the form
of elixirs, suspensions, emulsions, solutions, syrups etc. Composition intended for oral use
may be prepared according to any method known in the art for the manufacture of the
composition and such pharmaceutical compositions may contain in addition to active
ingredients, excipients such as diluents, disintegrating agents, binders, solubilizers,
lubricants, glidants, surfactants, suspending agents, emulsifiers, chelating agents, stabilizers,
flavours, sweeteners, colours etc. Some example of suitable excipients include lactose,
cellulose and its derivatives such as microcrystalline cellulose, methylcellulose, hydroxy
propyl methyl cellulose & ethylcellulose, dicalcium phosphate, mannitol, starch, gelatin,
polyvinyl pyrrolidone, various gums like acacia, tragacanth, xanthan, alginates & its
derivatives, sorbitol, dextrose, xylitol, magnesium stearate, talc, colloidal silicon dioxide,
mineral oil, glyceryl mono stearate, glyceryl behenate, sodium starch glycolate, cross
povidone, crosslinked carboxymethylcellulose, various emulsifiers such as polyethylene
glycol, sorbitol, fatty acid esters, polyethylene glycol alkylethers, sugar esters,
polyoxyethylene polyoxypropyl block copolymers, polysorbate, polyethoxylated fatty acid
monoesters, diesters and mixtures thereof.
Intranasal or pulmonary compositions according to present invention can be in the
form of liquid or solid or semisolid composition suitable for nasal administration. Liquid
composition can be aqueous, non-aqueous composition, suspension or emulsion; solid
composition can be in the form of powder and the like and semi solid composition can be in
form of gel and the like. Nasal/pulmonary compositions may also form in-situ gel. Said nasal
or pulmonary composition comprises compounds of formula (I) optionally with one or more
suitable excipients selected from in-situ gelling agent, mucoadhesive agent, polymer,
humectant, buffering agent, stabilizer, surfactant, preservative, thickening agent, solvents, cosolvents,
permeation enhancer, chelating agent, viscosity modifying agent, sweetener, taste
masking agent, solubilizer, flavoring agent, emulsifier and isotonicity agent.
Sterile compositions for injection can be formulated according to conventional
pharmaceutical practice by dissolving or suspending the active substance in a vehicle such as
water for injection, N -Methyl-2-Pyrrolidone, propylene glycol and other glycols, alcohols, a
naturally occurring vegetable oil like sesame oil, coconut oil, peanut oil, cotton sead oil or a
synthetic fatty vehicle like ethyl oleate or the like. Buffers, anti-oxidants, preservatives,
complexing agents like cellulose derivatives, peptides, polypeptides and cyclodextrins and
the like can be incorporated as required.
The dosage form can have a slow, delayed or controlled release of active ingredients
in addition to immediate release dosage forms.
The amount of active ingredient which is required to achieve a therapeutic effect will,
of course, vary with the particular compound, the route of administration, the subject under
treatment, and the particular disorder or disease being treated. The compounds of the
invention may be administered by oral, inhalation or parenteral route at a dose of from
0.0005 to 100 mg/kg per day, preferably from 0.0005 to 50 mg kg per day, more preferably
from 0.001 to 20 mg/kg per day, most preferably from 0.001 to 10 mg/kg per day. The dose
range for adult humans is generally from 5 g to 5 g per day, preferably dose range is 10g
to 2 g per day.
Dosage forms of presentation provided in discrete units may conveniently contain an
amount of compound of the invention which is effective at such dosage or as a multiple of
the same, for example units containing 5 g to 1000 mg.
In another embodiment present invention provides method of treating allergic and
non-allergic airway disease by administering a therapeutically effective amount of a
compound of formula (I) to a mammal, including human being, in need thereof. Allergic and
non-allergic airway diseases include allergic and non-allergic asthma, chronic obstructive
pulmonary disease (COPD), rhinitis, chronic bronchitis, emphysema, or asthma-like
syndrome such as coughing, wheezing or dyspnea.
In a preferred embodiment present invention provides a method for treating chronic
obstructive pulmonary disease and asthma by administering a therapeutically effective
amount of a compound of formula (I) to a mammal, including human being, in need thereof.
In a most preferred embodiment present invention provides a method for treating
chronic obstructive pulmonary disease by administering a therapeutically effective amount of
a compound of formula (I) to a mammal, including human being, in need thereof.
In another embodiment present invention provides the use of a compound of formula
(I) for the preparation of a medicament for treating allergic and non-allergic airway disease.
In a preferred embodiment present invention provides the use of a compound of
formula (I) for the preparation of a medicament for treating chronic obstructive pulmonary
disease and asthma.
In a most preferred embodiment present invention provides the use of a compound of
formula (I) for the preparation of a medicament for treating chronic obstructive pulmonary
disease.
Biological testing:
Biological example 1: in-vitro studies
Inhibition of p38 alpha MAPK activity: Time-resolved fluorescence resonance energy
transfer kinase standard assay (TR-FRET assay)
Compounds of present invention at various concentrations were premixed with
DMSO. The experiment was initiated by mixing 0.5% - 1.0% DMSO as vehicle/ compounds
with purified recombinant human p38 alpha MAPK (Millipore, USA) in the wells and 15
min incubation at room temperature. Thereafter, 30nM of Biotinylated GST-ATF2
(Activation transcription Factor2) and 100 of ATP were added in to the wells containing
reaction mixture, followed by reincubation for 60 minutes at RT. Reaction was terminated by
addition of 10 mM of EDTA and detection reagent containing anti-phosphotheronine ATF2
antibody (PerkinElmer®, USA) labeled with europium chelate and APC (Allophycocyanin)
labeled streptavidin, into the reaction mixture which was further incubated for 60 minutes at
room temperature. The degree of phosphorylation of the substrate (GST-ATF2) was
measured using Envision multimode reader (PerkinElmer®). Percentage inhibition of p38
kinase activity was calculated by determining ratio of specific europium 665nm energy
transfer signal to reference 615nm signal. Results are summarized in the table 2.
Table 2
Compound Concentration P38a
No Inhibition
ϊ ϊ +++++
2 ++
3 ++
4 ++++
5 +++++
6 +++++
7 +++++
8 +++++
9 +++++
10 +++++
1 1 +++++
12 +++++
13 +++++
14 +++++
15 +++++
16 +++++
17 ++++
18 +++++
19 +++++
20 +++++
2 1 +++++
22 +++++
23 +++++
24 +++++
25 +++++
26 +++++
27 +++++
28 +++++
29 +++++
30 +++++
3 1 +++++
32 +++++
33 +++++
34 +++++
35 +++++
36 +++++
37 +++++
38 +++++
39 +++++
40 +++++
Compound Concentration P38a
No Inhibition
4 1 ++++
42 +++++
43 +++++
44 +++++
45 +++++
46 ++++
47 ++++
48 +++++
49 +++++
50 +++++
5 1 +++++
52 4-4-4-4
53 1 +++
54 1 +
55 1 +
56 1 +++
57 1 4-4-4-4
58 1 +++
59 1 4-4-4-4
60 1 4-4-4-4
6 1 1 4-4-4-4
62 1 +++
63 100 +++4
64 1 4-4-
65 1 4-4-
66 1 +
67 1 4-4-4-4
68 1 4-4-4-
69 1 4-4-4-
70 1 4-4-4-
Observation: in- vitro data shows that compounds of present invention effectively inhibits p38
MAP kinase activity.
Biological example 2: in-vivo studies
In vivo efficacy evaluation of compounds in animal model of airway inflammation:
The tobacco smoke induced airway inflammation model is used for in-vivo efficacy
of compound. Many investigators have used acute tobacco smoke (TS) exposure in rodents
as models of airway inflammation for quick screening of anti-inflammatory therapies
Pharmacol Exp Ther. 2008; 324(3):921-9; J Pharmacol Exp Ther. 2010; 332(3):764-75;
Journal of Inflammation 2013, 10(Suppl 1):31 and Eur Respir J Suppl 2006; 663s:3850).
Given its position as predominant cause of COPD, animal models using TS exposure would
appear to be the logical choice for investigation {Respir Res. 2004; 2;5:18).
A: Efficacy studies in acute mouse model of airway inflammation
Mice were exposed to tobacco smoke (TS) in an acrylic chamber. Animals were
exposed to TS from 8, 12, 16 cigarettes on day 1, day 2, day 3 respectively. From day 4
onwards till day 11, animals were exposed to TS from 20 cigarettes per day. Like human
COPD associated inflammation, acute exposure of mice to TS induced significant
inflammatory cell, predominantly neutrophil recruitment to lungs as compared to air exposed
control mice (BALF neutrophil levels, nil in air control group vs 178+29.1 * 10 cells/animal
in smoke exposed vehicle group).
Lung delivery of test compound was achieved by whole body aerosol exposure for 25
minutes in a chamber. Mice were divided in different dose groups and exposed in a chamber
for 25 minutes with vehicle or Compound 12 (0.3mg/ml) or Compound 12 (3mg/ml). A total
quantity of 3.5ml of either vehicle or test compound formulation was nebulized in a
chambers to respective groups over 25 mins period. Test compounds were administered 2 hr
prior to TS exposure from day 6 to day 11. Bronchoalveolar lavage (BAL) was performed 24
hr post last TS exposure.
Trachea of animal was cannulated using catheter. Phosphate Buffer Saline (PBS) was
used as lavage fluid. A volume of 0.5ml was gently instilled and withdrawn and collected in
microcentrifuge tube placed on ice. This procedure was repeated further 2 times.
Lavage fluid was separated from cells by centrifugation and supernatant separated.
The cell pallet was resuspended in known volume of PBS. Cells in aliquot were stained using
Turk solution and total cell numbers were calculated by counting Turk stained aliquot under
microscope using haemocytometer.
The residual cell suspension was resuspended and slides prepared using cyto
centrifuge technique (Cytospin 4, Thermo Shandon). The slides were then fixed with
methanol, air dried and stained with May Grunwald Giemsa stain. Up to 300 cells were
counted and differentiated using standard morphometric techniques under light microscopy.
All results are presented at individual data for each animal and mean value calculated
for each group. Percentage inhibition for the neutrophil was calculated for Compound 12
treatment group against vehicle group. Results are summarized herein below:
The effect of treatment Compound 12 on cigarette smoke induced Neutrophil
accumulation in BAL Fluid.
Table 3
Treatment Formulation Exposure Neutrophil % Inhibition
strength Duration (*10
(Minutes)' cells/,ani.mal)
Compound 0.3 mg/ml 25 107+18.5 40
12
Compound 3 mg/ml 25 69.6+11.1 6 1
12
Values are Mean±SEM; NA: Not applicable
Observation: It was observed that compound of present invention was found effective in
inhibition of neutophil influx, an index of pulmonary inflammation. These results indicate
that compounds of present invention possess pulmonary anti-inflammatory activity.
B. (I) Efficacy studies in acute guinea pig model of airway inflammation
Guinea pigs were exposed to tobacco smoke (TS) in an acrylic chamber. Animals
were exposed to TS from 5, 10, 15 cigarettes on day 1, day 2, day 3 respectively. From day 4
onwards till day 11, animals were exposed to TS from 15 cigarettes per day. On 11 days of
exposure of guinea pig to TS, significant inflammatory cell recruitment, predominantly
neutrophils, to lungs was observed as compared to air exposed control guinea pig (BALF
neutrophil levels, 0.23±0.052*106 cells/animal in air control group vs 1.9±0.42*
10 cells/animal in smoke exposed vehicle group).
Lung delivery of test compound was achieved by whole body aerosol exposure for 75
minutes in a chamber. Guinea pig were divided in different dose groups and exposed in a
chamber for 75 minutes with vehicle or Compound No 43 (6 mg/ml). A total quantity of 7.0
ml of either vehicle or test compound formulation (suspension formulation with D90< 5,
with Malvern Mastersizer®) was nebulized in chambers to respective groups over 75 mins
period. Test compound was administered 2 hr prior to TS exposure from day 6 to day 11.
Bronchoalveolar lavage (BAL) was performed 24 hr post last TS exposure.
Trachea of animal was cannulated using catheter. Phosphate Buffer Saline (PBS) was
used as lavage fluid. A volume of 5.0 ml was gently instilled and withdrawn and collected in
microcentrifuge tube placed on ice. This procedure was repeated further 5 times.
Lavage fluid was separated from cells by centrifugation and supernatant separated.
The cell pallet was resuspended in known volume of PBS. Cells in aliquot were stained using
Turk solution and total cell numbers were calculated by counting Turk stained aliquot under
microscope using haemocytometer.
The residual cell suspension was resuspended and slides prepared using cyto
centrifuge technique (Cytospin 4, Thermo Shandon). The slides were then fixed with
methanol, air dried and stained with May Grunwald Giemsa stain. Up to 300 cells were
counted and differentiated using standard morphometric techniques under light microscopy.
All results are presented at individual data for each animal and mean value calculated for
each group. Percentage inhibition for the neutrophil was calculated for compound no 43
treatment group against vehicle group. Results are summarized herein below:
The effect of treatment compound no 43 on cigarette smoke induced inflammatory
cell accumulation in BAL Fluid.
Table 4
Treatment Concentration Exposure Effect on inflammatory cell influx
Duration
(Minutes) Neutrophil %inhib
(*10 cells)
Vehicle NA 75
Compound no 43 6 mg/ml 75 0.8±0.20 57
Values are Mean±SEM; NA: Not applicable
Observation: It was observed that compound of present invention was found effective in
inhibition of neutrophil influx, an index of pulmonary inflammation in guinea pig model of
airway inflammation. These results indicate that compounds of present invention possess
pulmonary anti-inflammatory activity.
(II) Efficacy studies in chronic model of COPD in guinea pigs.
Guinea pigs were exposed to tobacco smoke (TS) and Lipopolysaccharide (LPS) in
an acrylic chamber. Exposure to TS and LPS is given in following manner in a week for a
total of 18 weeks.
wk 1
wk 18
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
TS TS LPS TS TS LPS NIL
Lung delivery of test material was achieved by whole body aerosol exposure for 50
minutes in a chamber. Guinea pig were divided in different dose groups and exposed to either
vehicle or compound no 43 (3 mg/ml). A total quantity of 7.0 ml of either vehicle or
compound no 43 (suspension formulation with D90< 5, with Malvern Mastersizer®) was
nebulized in chambers to respective groups over 50 mins period. Compound no 43 or vehicle
was administered 2 hr prior to TS/LPS exposure once daily from week 9 to week 18. Control
animals were exposed to room air instead of TS and PBS instead of LPS. Lung function and
bronchoalveolar lavage (BAL) for each animal was performed 24 hr post last TS exposure.
Lung function assessment in anesthetized and tracheotomized animal was carried out
using PFT maneuvers (BUXCO, USA) for determination of various parameters such as
Functional Residual Capacity (FRC), Residual volume (RV), Pressure volume and flow
volume relationships.
Trachea of animal was cannulated using catheter. Phosphate Buffer Saline (PBS) was
used as lavage fluid. A volume of 5.0 ml was gently instilled and withdrawn and collected in
microcentrifuge tube placed on ice. This procedure was repeated further 5 times.
Lavage fluid was separated from cells by centrifugation and supernatant separated.
The cell pallet was resuspended in known volume of PBS. Cells in aliquot were stained using
Turk solution and total cell numbers were calculated by counting Turk stained aliquot under
microscope using haemocytometer.
The residual cell suspension was resuspended and slides prepared using cyto
centrifuge technique (Cytospin 4, Thermo Shandon). The slides were then fixed with
methanol, air dried and stained with May Grunwald Giemsa stain. Up to 300 cells were
counted and differentiated using standard morphometric techniques under light microscopy.
All results are presented at individual data for each animal and mean value calculated
for each group. Percentage inhibition for the neutrophil was calculated for compound no 43
treatment group against vehicle group. Results are summarized herein below:
A. Effect of treatment of compound no 43, on BALF fluid inflammatory cell influx in guinea
pigs.
Treatment Concentration Exposure Duration Neutrophil %
(mg/ml) (Minutes) (*10 cells) inhib"
Vehicle NA 50 5.9±0.75
compound no 3 50 4.0±0.70 32
43
Values are Mean±SEM; NA: Not applicable
B. Effect of treatment of compound no 43, on lung function parameters, Functional Residual
Capacity (FRC), Residual Volume (RV), Inspiratory Capacity (IC) to Total Lung Capacity
(TLC) ratio and Residual volume (RV) to total lung capacity (TLC) ratio is given in Fig 1
and 2. (Values are Mean±SEM)
Observation: In a chronic COPD model, compound of present invention exerted effect in
reduction of neutrophil influx to lung tissue, significantly improves lung function aspects
associated with COPD.
CLAIMS
1. A Compound of formula (I)
their pharmaceutically acceptable salts and their isomers, stereoisomers, atropisomers,
conformers, tautomers, polymorphs, hydrates, and solvates;
wherein,
Y is C=O or C(Z');
Q is C or N, when Y is C=0 then Q is N;
When Y is C=0, Z is selected from hydrogen, -(Ci-C )alkyl, branched-(C3-C )alkyl, -
(C3-C6)cycloalkyl, -(Ci-C3)alkyl(C3-C6)cycloalkyl, -(Ci-C6)alkyl-OH, -(Ci-C6)alkyl-SH,
-C(0)CH 2R4, -(Ci-C6)alkyl-NR5R6, -(Ci-C6)alkyl-aryl, -(Ci-C6)alkyl-heteroaryl, -(QC
6)alkyl-C0 2H, -(Ci-C6)alkyl-C0 2R , -(Ci-C6)alkyl-C(0)NR 5R6, -C(0)NR 5R6, -C0 2R , -
COR , -(Ci-C6)alkyl-OR , -(Ci-C6)alkyl-S(0) R , -S(0) m-R , -S(0) mN(R3)-R , -
S(0) mNR5R , aryl and heteroaryl, wherein said aryl or heteroaryl may be further
optionally substituted by 1-3 substituents independently selected from R ;
or when Y is C(Z'), Z and Z' together forms a 5 or 6 membered aromatic ring system
having 1 to 3 heteroatoms independently selected from O, S(0) or N and the said ring is
optionally substituted by 1-3 substituents independently selected from
P is a cyclic ring, which is selected from
Where * denotes point of attachment to nitrogen;
Ra, R , and Rc are independently selected from hydrogen, halogen, -(Ci-C )alkyl,
branched-(C 3-C )alkyl, -(C 3-C )cycloalkyl, aryl, heteroaryl, heterocyclic, -(C1-C )alkylaryl,
-(Ci-C6)alkyl-heteroaryl, hydroxyl, -CF3, -OCF3, -N0 2, -C(0)-(Ci-C 6)alkyl, -C(O)-
(C3-C6)cycloalkyl, -C(0)CH 2R4, -NR5R6, -N(R3)C(0)-R , -N(R3)S(0) m-R , -N(R3)C(0)-
N(R3)-R , -N(R3)C(S)N(R3)-R , -OR , -C0 2H, -C0 2R , -C(0)-NR 5R6, -SH, -S(0) -R , -
S(0) mN(R3)-R , -S(0) m-NR5R6, -CN, -CHO, -(Ci-C6)alkyl-R4 and -(Ci-C6)alkyl-NR5R6,
wherein each aryl, heterocyclic or heteroaryl may be further optionally substituted with 1-
3 substituents independently selected from halogen, -(Ci-C )alkyl, branched-(C 3-
C )alkyl, aryl, heteroaryl, heterocyclic, hydroxyl, -CF3, -OCF3, -OR , -0-(Ci-C )alkyl-R8,
-N0 2, -C(0)-(Ci-C 6)alkyl, -C(0)CH 2R4, -NR5R6, -C0 2H, -C0 2R , -C(0)NR 5R6, -
N(R3)C(0)-R , -N(R3)S(0) m-R , -SH, -S(0) -R , -S(0) mN(R3)-R , -CN, -CHO, -(d-
C )alkyl-OR7, -(Ci-C )alkyl-halogen and -(Ci-C6)alkyl-NR5R ; or any two substituents of
Ra, Rb, and Rc may form a saturated, partially saturated or unsaturated monocyclic ring,
which may contain 0, 1, 2 or 3 ring heteroatoms selected from O, S(0) or N;
W is -(CH2)t, -(CH2)mCO or -(CH2)mS(0) m;
R is selected from hydrogen, -(Ci-C )alkyl, branched-(C3-C )alkyl, halogen, -0(Ci-
C6)alkyl, -CF3, -OCF3 and hydroxyl;
Ri and R2 are independently selected from hydrogen, hydroxyl, -(Ci-C3)alkyl, branched-
(C3-C )alkyl and -(C3-C )cycloalkyl or Ri and R2 together with the carbon to which they
are attached, forms a -(C3-C )cycloalkyl ring in a spiro manner;
R3 is independently selected from hydrogen, -(Ci-C3)alkyl, branched-(C3-C )alkyl and -
(Ci-C3) alkyl(C3-C ) cycloalkyl, glucuronate;
R4 is independently selected from hydroxyl, -SH, -OR , -NR5R6, -S(0) -R , -S(0) -(Ci-
C6)alkyl-C0 2(Ci-C6)alkyl, -S(0) -(Ci-C6)alkyl-OH, -S(0) -(Ci-C6)alkyl-C0 2H, -
N(R3)C(0)-R , -N(R3)S(0) m-R , -0-(Ci-C 6)alkyl-C0 2(Ci-C6)alkyl, -0-(Ci-C 6)alkyl-OH
and -0-(Ci-C 6)alkyl-C0 2H;
R and R are independently selected from hydrogen, -(Ci-C )alkyl, branched-(C3-
C6)alkyl, -COR , -C(0)NR 5R6, -S(0) mR , -(Ci-C6)alkyl-(C3-C6)cycloalkyl, -(C3-
C )cycloalkyl, aryl and heteroaryl or R 5 and R are taken together with nitrogen to form a
3 to 8 membered monocyclic or 8 to 12 membered bicyclic heterocycle ring, wherein the
said mono and bicyclic ring contain 0, 1, 2 or 3 ring heteroatoms selected from O, S(0)
or N and the said ring is optionally substituted by 1-3 substituents independently selected
from R8;
R is independently selected from -(Ci-C )alkyl, -(Ci-C )alkyl-OH, branched-(C3-
C )alkyl, -(C3-C )cycloalkyl, -(Ci-C6)alkyl-(C3-C )cycloalkyl, aryl and heteroaryl;
R is independently selected from hydrogen, halogen, hydroxyl, -CN, -CHO, -N0 2, -( -
C )alkyl, -(C3-C )cycloalkyl, -(Ci-C6)alkyl-(C3-C6 )cycloalkyl, aryl, heteroaryl,
heterocyclic, -C(0)CH 2R4, -OR , -SH, -S(0)„-R 7, -CF3, -OCF3, -C0 2H -COR , -C0 2R , -
C(0)NR 5R6, -S(0) mN(R3)-R and -NR5R6, wherein the said (Ci-C6)alkyl, aryl,
heterocyclic and heteroaryl may be further substituted with 1-3 substituents
independently selected from R9.
R 9 is independently selected from R7, halogen, hydroxyl, -(Ci-C )alkyl-OH, -N0 2 -SH, -
OR , -0(Ci-C 6)alkyl-R4, -OC(0)-R , -0(Ci-C 6)alkyl-C0 2R , -0(Ci-C 6)alkyl-C0 2H -
0(Ci-C 6)alkyl-C(0)-NR 5R6, -OS(0) m-R7, -C0 2R , -C0 2H -C(0)-R , -C(0)-NR 5R6, -
S(0) -R7, -S(0) (C1-C )alkyl-R4, -S(0) (C1-C )alkyl-C(0)NR 5R6, -S(0) (C1-C )alkyl-
C0 2R , -S(0) (Ci-C6)alkyl-C0 2H, -NR5R6, -S(0) m-NR5R6, -N(R3)C(0)-R , -
N(R3)C(0)N(R 3)-R , -N(R3)C(S)N(R3)-R ,-N(R3)C(0)(Ci-C 6)alkyl-aryl,-N(R3)S(0) m-R „
OS0 3H and O-glucuronate;
m is 1 or 2;
n is 0, 1 or 2;
t is 2 or 3.
2. The compound as claimed in claim 1, wherein Q is N.
3. The compound as claimed in claiml, wherein;
Y is C=O or C(Z');
Q is C or N; when Y is C=0 then Q is N;
When Y is C=0, Z is selected from hydrogen, -(Ci-C )alkyl, branched-(C3-C )alkyl, -
(C3-C6)cycloalkyl, -(Ci-C3)alkyl(C3-C6)cycloalkyl, -(Ci-C6)alkyl-OH, -(Ci-C6)alkylaryl,
-(Ci-C6)alkyl-C(0)NR 5R6, S(0) m-R and aryl;
or when Y is C(Z'), Z and Z' together forms a 5 or 6 membered aromatic ring system
having 1 to 3 heteroatoms independently selected from S(0) or N and the said ring is
optionally substituted by 1-2 substituents independently selected from R ;
P is a c clic ring, which is selected from
Where * denotes point of attachment of nitrogen;
Ra, R , and Rc are independently selected from hydrogen, halogen, -(Ci-C )alkyl,
branched-(C 3-C6)alkyl, -(C3-C6)cycloalkyl, hydroxyl, -N(R3)S(0) m-R , -N(R3)COR
and -OR ;
W is -(CH2)t or -(CH2)mCO;
R is hydrogen or -(Ci-C )alkyl;
R and R are independently selected from hydrogen and hydroxyl;
R3 is independently selected from hydrogen and glucuronate;
R4 is selected from hydroxyl and -NR5R ;
R 5 and R is independently selected from hydrogen, -(Ci-C )alkyl and -COR or
R 5 and R are taken together with nitrogen to form a 3 to 8 membered monocyclic
heterocycle ring, wherein the said monocyclic ring contain 0, 1, 2 or 3 ring
heteroatoms selected from O or N;
R is selected from -(Ci-C6)alkyl, -(C3-C6)cycloalkyl, -(Ci-C6)alkyl-OH and
branched-(C 3-C )alkyl;
is independently selected from hydrogen, -(C3-C )cycloalkyl, aryl, heteroaryl, -
CF3,
-C0 2R and -NR5R , wherein the said aryl or heteroaryl may be further substituted
with 1-3 substituents selected from R9.
R 9 is independently selected from halogen, R , hydroxyl, -OR -0(Ci-C )alkyl-R4, -
S(0) -R , -S(0) (Ci-C6)alkyl-R4 , -(Ci-C6)alkyl-OH and O-glucuronate;
m is 1 or 2;
n is 0;
t is 2 or 3.
4. The compound as claimed in claim 1, which is selected from the group consisting of:
1-[ -tert-butyl- 1-(4-methylphenyi )-lH-pyrazol-5 -yl] -3-(7- {2-oxo-2- [3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-tert-butylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-cyclohexylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-(7-{2-oxo-2-[3-
(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-(7-{2-[3-(2-methoxyphenyl)-
5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-oxoethoxy}-2,3-
dihydro- 1H-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-(2-
hydroxyethyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
1-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-[7-(2-{3-[2-
(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}-
2-oxoethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-
(2-methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-
oxoethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-
[2-(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}-2-oxoethoxy)-2,3-dihydro-lH-inden-4-yl]urea
1-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-[2-
(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}-
2-oxoethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-(7-{2-[3-(2-{[2-(morpholin-4-
yl)ethyl]sulfanyl}phenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]-2-oxoethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-[2-
(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(2-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
1-{7-[2-(4-benzyl-3-oxopiperazin- 1-yl)ethoxy] -2,3-dihydro- 1H-inden-4-yl }-
3-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]urea
l-[3-tert-butyl-l-(4-methoxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
l-[3-tert-butyl-l-(4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
1-[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl] -3-{7-[2-(3-oxo-4-
phenylpiperazin-l-yl)ethoxy]-2, 3-dihydro- lH-inden-4-yl}urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-{2-[2-
(morpholin-4-yl)ethoxy]phenyl}-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopentylmethyl)-3-oxopiperazin- 1-yl]ethoxy}-2,3-dihydro- lH-inden-4-
yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclobutylmethyl)-3-oxopiperazin-l-yl]ethoxy}-2, 3-dihydro- lH-inden-4-
yl)urea
l-[3-tert-butyl-l-(4-ethylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(2-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-
[2-(methylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-
(2-methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-
(2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-
(2-propoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl] -3-(7- {3-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]propoxy}-2,3-dihydro- 1H-inden-
4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-[2-(2-
hydroxyethoxy)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-chloro-4-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-(7-{2-[3-(2-butoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)-3-[3-tert-butyl-l-(4-
methylphenyl)-lH-pyrazol-5-yl]urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-[2-
(propylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(4-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-
[2-(propylsulfanyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(2,4-
dihydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-4-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
N-(5-tert-butyl-3- {[(7- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)methanesulfonamide
N-(5-tert-butyl-3-{[(7-{2-[3-(2-hydroxyphenyl)-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy} -2,3-dihydro- 1Hinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)methanesulfonamide
N-(5-tert-butyl-3-{[(7-{3-[4-(cyclopropylmethyl)-3-oxopiperazin-lyl]
propoxy} -2,3-dihydro- lH-inden-4-yl)carbamoyl]amino}-2-
methoxyphenyl) methanesulfonamide
N-[5-tert-butyl-2-methoxy-3-({[7-(2-{3-[2-(propylsulfanyl)phenyl]-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}ethoxy)-2,3-dihydro-lHinden-
4-yl]carbamoyl} amino)phenyl]methanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)ethanesulfonamide
N-{5-tert-butyl-3-[({7-[2-(4-butyl-3-oxopiperazin-l-yl)ethoxy]-2,3-dihydrolH-
inden-4-yl}carbamoyl)amino]-2-methoxyphenyl} methanesulfonamide
N-[5-tert-butyl-2-methoxy-3-({[7-(2-{3-[2-(methylsulfanyl)phenyl]-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}ethoxy)-2,3-dihydro-lHinden-
4-yl]carbamoyl} amino)phenyl]ethanesulfonamide
N-(5-tert-butyl-3-{[(7-{2-[3-(3-hydroxyphenyl)-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)methanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[3-{4-[(2-hydroxyethyl)sulfanyl]phenyl }-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)methanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[3-(5-chloro-2-hydroxyphenyl)-5 ,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)methanesulfonamide
N-(5-tert-butyl-3-{[(7-{2-[3-(2,4-dihydroxyphenyl)-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)ethanesulfonamide
N-[5-tert-butyl-2-methoxy-3-({[7-(2-{3-[2-(propylsulfanyl)phenyl]-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl}ethoxy)-2,3-dihydro-lHinden-
4-yl]carbamoyl} amino)phenyl] ethanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[3-(5-chloro-2-hydroxyphenyl)-5 ,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)carbamoyl]amino }-2-methoxyphenyl)ethanesulfonamide
N-[5-({[7-({[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}acetyl)-4, 5,6,7-
tetrahydrothieno[3,2-c]pyridin-2-yl] acetamide
l-[3-tert-butyl-l-(3-chloro-4-methoxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-
oxo-2-[3-(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
ethyl 6-( {[7-( {[3-tert-butyl- 1-(4-methylphenyl)- lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}acetyl)-2-
[(cyclopropylcarbonyl)amino]-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-
carboxylate
N-[5-( {[7-( {[3-tert-butyl- 1-(4-cyclohexylphenyl)- 1H-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}acetyl)-4, 5,6,7-
tetrahydrothieno[3 ,2-c]pyridin-2-yl] acetamide
1-[3-tert-butyl-l-(3-chloro-4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-oxo-
2-[3-(trifluoromethyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-{7-[2-oxo-2-(3-
phenyl-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethoxy]-2,3-
dihydro- 1H-inden-4-yl }urea
l-(3-tert-butyl-l-phenyl-lH-pyrazol-5-yl)-3-(7-{2-[3-(3-chloro-4-
methoxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-2-
oxoethoxy}-2,3-dihydro-lH-inden-4-yl)urea
1-[3-tert-butyl- 1-(4-methylphenyl) -1H-pyrazol-5 -yl] -3-{7-[2-(3-oxo-4-
propylpiperazin- 1-yl)ethoxy] -2,3-dihydro- 1H-inden-4-yl }urea
l-[3-tert-butyl-l-(4-fluorophenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
1-(3-tert-butyl- 1-phenyl- 1H-pyrazol-5-yl)-3 -(7- {2-[4-(cyclopropylmethyl)-
3-oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)urea
l-[3-tert-butyl-l-(2-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3 -oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-
(2,4-dihydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
N-(5-tert-butyl-3- {[(7- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
methoxyphenyl)cyclopropanecarboxamide
l-[3-tert-butyl-l-(3-chloro-4-hydroxyphenyl)-lH-pyrazol-5-yl]-3-{7-[2-(3-
cyclohexyl-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethoxy]-2,3-
dihydro- 1H-inden-4-yl }urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
6-methyl-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(naphthalenl-
yl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-
dihydro- 1H-inden-4-yl)urea
1-[3-tert-butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl] -3-{7-[2-(3-cyclohexyl-
5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)ethoxy]-2,3-dihydro-lHinden-
4-yl}urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(3-methyll-
benzofuran-2-yl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(3,4,5-trimethoxyphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea
1-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(cyclopropylmethyl)-3-oxopiperazin- 1-yl]ethoxy }-2,3-dihydro- 1H-inden-4-
yl)urea methanesulfonate (1:1)
N-{5-tert-butyl-3-[({7-[2-(3-cyclohexyl-5,6-dihydro[l,2,4]triazolo[4,3-
a]pyrazin-7(8H)-yl)ethoxy]-2,3-dihydro-lH-inden-4-yl}carbamoyl)amino]-
2-methoxyphenyl}methanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[3-(5-chloro-2-hydroxyphenyl)-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-6-methyl-2,3-
dihydro- 1H-inden-4-yl)carbamoyl]amino }-2-
methoxyphenyl)methanesulfonamide
N-(5-tert-butyl-2-methoxy-3-{[(7-{2-[3-(naphthalen-l-yl)-5,6-
dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-lHinden-
4-yl)carbamoyl]amino }phenyl)methanesulfonamide
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[4-
(ethylsulfonyl)-3-oxopiperazin-l-yl]ethoxy}-2,3-dihydro-lH-inden-4-
yl)urea
2-[7-(2-{ [7-({ [3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}ethyl)-5,6,7,8-
tetrahydro[l,2,4]triazolo[4,3-a]pyrazin-3-yl]-4-chlorophenyl
hexopyranosiduronic acid
N-{[3-tert-butyl- 1-(4-methylphenyl)- 1H-pyrazol-5-yl]carbamoyl }-N-(7- {2-
[3-(5-chloro-2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-
7(8H)-yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)hexopyranuronosylamine
N-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-N-[(7-{2-[3-(5-chloro-
2-hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]ethoxy}-2,3-dihydro-lH-inden-4-yl)carbamoyl]hexopyranuronosylamine
2-{4-[2-( {7-[( {5-tert-butyl-2-methoxy-3-
[(methylsulfonyl)amino]phenyl}carbamoyl)amino]-2,3-dihydro-lH-inden-4-
yl }oxy)ethyl] -2-oxopiperazin- 1-yl }-N,N-dimethylacetamide
2-[4-(2-{ [7-({ [3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-
yl]carbamoyl}amino)-2,3-dihydro-lH-inden-4-yl]oxy}ethyl)-2-
oxopiperazin- 1-yl]-N,N-dimethylacetamide
N-{5-tert-butyl-3-[({7-[2-(4-cyclopropyl-3-oxopiperazin-l-yl)ethoxy]-2,3-
dihydro- 1H-inden-4-yl }carbamoyl)amino] -2-
methoxyphenyl }methanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
hydroxyphenyl)ethanesulfonamide
N-(5-tert-butyl-3- {[(7- {2-[4-(cyclopropylmethyl)-3-oxopiperazin- 1-
yl]ethoxy }-2,3-dihydro- 1H-inden-4-yl)carbamoyl] amino }-2-
methoxyphenyl)ethenesulfonamide
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-[7-(2-{3-[2-
(hydroxymethyl)phenyl]-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl}ethoxy)-2,3-dihydro-lH-inden-4-yl]urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{3-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-
yl]propoxy} -2,3-dihydro- lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(pyridin-2-
yl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-dihydro-
1H-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(2-
ethylphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-2,3-
dihydro- 1H-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(4-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro-lH-inden-4-yl)urea
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro- lH-inden-4-yl)urea methanesulfonate
l-[3-tert-butyl-l-(4-methylphenyl)-lH-pyrazol-5-yl]-3-(7-{2-[3-(5-chloro-2-
hydroxyphenyl)-5,6-dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]ethoxy}-
2,3-dihydro- lH-inden-4-yl)urea hydrochloride;
and pharmaceutically acceptable salts thereof.
5. A pharmaceutical composition comprising a therapeutically effective amount of one or
more compound as claimed in claim 1, in admixture with a pharmaceutically acceptable
adjuvant or carrier.
6. A method of treating allergic and non-allergic airway diseases in a mammal, including
human being, the method comprising administering a therapeutically effective amount of
a compound as claimed in claim 1.
7. The method as claimed in claim 6, wherein allergic and non-allergic airway disease is
selected from chronic obstructive pulmonary disease and asthma.
8. Use of a compound as claimed in claim 1, for the preparation of a medicament for
treating allergic and non-allergic airway diseases.
9. Use of a compound as claimed in claim 8, wherein allergic and non-allergic airway
disease is selected from chronic obstructive pulmonary disease and asthma.
10. A compound of formula (I), its process for the preparation and pharmaceutical
composition, as herein described with reference to the examples accompanying the
specification.